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DT/DOXO+TNF Doxorubicin + Tumour Necrosis Factor alpha 
FASAY Functional analysis of separated alleles in yeast 
FLUC/RLUC Firefly Luciferase/Renilla Luciferase 
G418 Geneticin 
IкB Inhibitory Kappa B Protein 
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MDM2 Mouse Double Minute 2 
N-terminal Amino terminal domain 
PBM Protein binding Microarrays 
PeT Paired end tags 
pur/pyr purine/pyrimidine 
qPCR Quantitative Polymerase chain reaction 
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RE Response Element 
RHD Rel homology domain 
RTCA Real time cell analysis 
RT-PCR Reverse transcriptase Polymerase chain reaction 
Selex Systematic Evolution of Ligands By Exponential Enrichment 
TA Transactivation Assay or Transactivation Active (e.g. TAp53) 
TF Transcription factor 
TLR Toll-like receptors 
TNFα Tumor Necrosis Factor alpha 
TSS Transcriptional Start Site 
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ABSTRACT 
p53 and NF-кB families of Transcription Factors (TFs) are among the most studied proteins in 
tumour biology, typically known to function as antagonists, although recent studies identified 
example of positive, even cooperative interactions. p53 and NF-кB act as dimer or dimer of 
dimers, bind cis regulatory elements (referred herein as Response Elements –REs-) of which 
multiple versions exist in the genome, and coordinate very large networks of target genes, 
through highly regulated transactivation specificities. TAp53 is a tumour suppressor activated 
upon genotoxic and physiological stress and involved primarily in deciding senescence, cell 
cycle arrest or apoptosis as cell fate; the NF-кB proteins are involved in cell survival, 
proliferation and innate immunity responses. In our study we tried to elucidate in detail the 
intrinsic nucleotide preferences of p53 and NF-кB as sequence specific TFs and their impact 
on transactivation specificity. Selecting various in vivo validated cognate REs and testing 
various ad-hoc sequence permutations, we evaluated the role of identity and positioning of 
nucleotides in transactivation potential and specificity. To this aim different transcription 
assays were used, starting from a defined assay in yeast where p53 or NF-kB protein levels 
and the sequence of the RE are the only variables.  
 With human wild type p53, I tested various REs used in co-crystallization studies 
probing nucleotide positions that are not directly contacted by the p53 DNA binding domain, 
to explore the effect of DNA conformational shifts on transactivation. Also, we investigated 
the effect on strength and direction of p53-induced transcription of changes in the nucleotides 
flanking an RE, selected based on torsional flexibility measurements.  
 For the NF-кB family, relA/p65 and NFKB1/p50 were tested as single proteins or 
when co-expressed using a panel of REs selected based on different DNA binding affinities. 
The correlation between DNA binding and transactivation potential was examined. Further, 
the negative modulator IкBα was co-expressed and its impact measured as a function of NF-
кB protein type, expression level, or RE being tested.  
 Both for p53 and NF-кB studies, we confirmed that the hierarchical organization of 
nucleotides within REs observed with yeast was reasonably well conserved in A549, H1299 
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or MCF7 human cells using transient transfection and/or treatments to activate endogenous 
p53 or NF-кB. 
 Finally, I contributed to an ongoing study focusing on the interplay between p53 and 
NF-кB at the transcriptional level. Using microarrays and quantitative PCR we had observed 
highly synergistic expression of a group of genes involved potentially in metastasis, cell 
growth and proliferation upon combined treatment of MCF7 cells with doxorubicin, a 
chemotherapeutic agent, and TNFα, an inflammatory cytokine. I have studied regions of the 
promoters of several such synergistic genes carrying putative p53 and NF-кB binding sites to 
study cis-mediated regulation of gene expression. This led to the investigation of cell type 
specific effects and the contribution of cofactors in the transcriptional synergy. 
 
Thus the main goals of my thesis work have been: 
1. To evaluate the hierarchy of nucleotides in the DNA code read by p53 and NF-кB as 
sequence-specific transcription factors.  
2. Investigate the conservation of transactivation capacity and specificity between yeast 
and mammalian systems for the tested panel of REs. 
3. Estimate the contribution of physical properties of DNA (torsional rigidity or 
flexibility) contiguous to a p53 RE in influencing the strength and the direction of 
transcription. 
4. Explore the molecular mechanisms underlying transcriptional synergy in response to 
Doxorubicin and TNFα treatment 
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A systematic evaluation of variably organized 
p53 and NF-κB Response Elements 
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INTRODUCTION 
Using yeast to study human sequence-specific transcription factors 
Transcription is a phenomenon involving dynamic, spatial and temporal organization of 
transcription factors and cofactors on the open chromatin regions scanned by RNA 
polymerases to synthesize the transcripts. Most of the trans factors involved recognize 
specific DNA codes called Response Elements (REs) within the promoter or enhancer region 
of a gene to initiate transcription or modulate constitutive transcription rates as part of the 
responses to specific stimuli. An RE comprises ~6-10 nucleotide motifs with various degree 
of variability at individual positions resulting in rather loose consensus sequences, usually 
summarized by weight matrices or logos (1). Hence, TFs can exhibit variable DNA binding 
affinities towards specific target REs. Many studies have drawn a correlation between the 
identity of nucleotides at specific positions within an RE and relative binding behaviour of a 
TF. However, DNA binding affinity may not accurately predicts the transcriptional 
responsiveness of a promoter, even in defined gene reporter assays, especially for TFs that act 
as oligomers (dimers or tetramers). The actual contribution of cis elements in controlling gene 
expression in vivo, particularly the coordination of large response networks by master genes, 
can be very elusive (2). Indeed, many cis- and trans- factors contribute to promoter 
accessibility, RNA polymerase II recruitment, transcriptional initiation, and elongation.  
Considering the primary sequence, enhancer and promoters are composite arrangements of 
multiple REs. Hence, features like spacer length separating two or more TF binding sites and 
organization of REs with respect to the transcriptional start site (TSS) impact on binding and 
transactivation potentials. While various bioinformatics tools and software are available to 
predict the closeness of input DNA sequences to consensus DNA motifs for transcription 
factors, such as Jaspar, TOMTOM and TRANSFAC (http://www.gene-
regulation.com/pub/databases.html), the current tools almost invariably rely on position 
weight matrices assuming independent contributions of each nucleotide to the score of a 
binding site. Furthermore, while some tools evaluate co-occurrences of binding sites, there is 
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little information for predicting the impact of closely spaced binding sites on promoter 
dynamics.  
 
Yeast as a tool to dig on functionality of Response Elements 
The yeast S. cerevisiae is a recognized model system for understanding aspects of the biology 
of human proteins using complementation assays or ectopic expression and functional assays 
even for the cases where a clear orthologous yeast gene is absent (3-6). For example, 
techniques such as the Functional Analysis of Separated Alleles in Yeast (FASAY) have been 
developed and proven to be a reliable tool to evaluate the functional impact of various p53 
mutants, one of the most frequently mutated tumour suppressor protein in cancer (7). Briefly, 
the assay exploits the ADE2 yeast gene, whose transcription is placed under wild type p53 
control by an engineered promoter. Lack of ADE2 expression resulting from the expression of 
loss-of-function human p53 cDNA alleles in yeast would lead to small red colonies on plates 
containing low adenine amounts due to building up of a coloured metabolic intermediate. p53-
dependent ADE2 expression results in yeast cells becoming proficient for adenine 
biosynthesis giving rise to larger, white colonies. This rapid colour assay is combined with a 
gap repair approach so that each transformant colony growing on the selective media has 
captured and constitutively expresses a single p53 cDNA allele, obtained from RT-PCR from 
human RNA samples, including cancer biopsies, hence the FASAY acronym (8). The basic 
protocol has been refined over the years, for example introducing a split version of the gap 
repair assay that evaluates separately two portions of the p53 cDNA and is thus more efficient 
with low quality RNA, as a shorter cDNA amplicon is needed (9). A second improvement 
consisted in modified p53-responsive promoters that incorporate different versions of p53 REs 
that led to the identification of p53 mutants that discriminate binding sites (10, 11). The assay 
has been used to identify functionally inactivating p53 mutations from clinical samples (12, 
13), or to generate mutation spectra after in vitro damage of the p53 cDNA with specific drugs 
(14). The assay has been further modified to include the co-expression of MDM2, a key 
negative regulator of p53 (15), or 53BP1, BRCA1, BRCA2, p53 interacting proteins that are 
important cofactors in the DNA damage response (16-19). A similar experimental approach 
has been developed more recently to test several other mammalian transcription factors 
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through their expression in yeast, including Estrogen Receptors, homeodomain NKX2-5, 
bHLH HAND1/E12/E47 (20, 21). 
 
Delitto Perfetto: Orchestrating cis regulatory elements in yeast 
Delitto Perfetto is a method that utilizes oligonucleotides or longer donor DNA molecules to 
target chosen genomic loci in yeast exploiting homologous recombination. With this approach 
site specific mutations, small or large deletions, or insertions method can be rapidly 
introduced at chromatin sites by a two-step cloning free protocol (22). The whole technique 
takes 5-6 days to remove a previously integrated double marker cassette (CORE), containing 
the genes KlURA3 (counter-selectable by 5-fluoro-orotic acid, 5FOA) and kanMX4 (reporter, 
providing resistance to G418) from a previously targeted yeast locus. In the high-efficient 
version of the assay, the cassette (termed ICORE) also contains the cDNA for the homing 
endonuclease I-SceI under an inducible promoter and the unique target site for this enzyme. 
Hence, prior to transformation of yeast with the targeting molecules, I-SceI expression is 
induced resulting in a single double strand break at the site of ICORE integration that greatly 
enhances the frequency of targeting events, which are again selected on 5FOA plates. The 
replacement of the ICORE cassette can be accomplished using double-strand or even single-
strand DNA molecules. Thirty nucleotide of homology at both ends of the donor molecules 
corresponding to sequences flanking the ICORE cassette integration site are sufficient for the 
homologous recombination process in wild type yeast (22). Hence, this approach is well-
suited to target promoter regions and introduce 10-20 nucleotide-long REs of interest to study 
TFs. To this end, a yeast reporter strain derived from the FASAY assay has been modified to 
introduce ICORE upstream of the minimal promoter that can be rendered p53-dependent by 
the placement at the site of p53 REs (23). In a later development the color ADE2 reporter gene 
has been replaced with the quantitative Firefly luciferase cDNA (LUC) to generate yLFM-
ICORE that serves as the starting strain for all RE targeting performed in this work. Again, 
yLFM-ICORE is transformed with synthetic oligonucleotides leading to excision of ICORE 
cassette from the target locus imparting 5-FOA resistance to the cells. Colonies appearing on 
5-FOA plates are then replica plated both on rich YPDA plates and on YPDA plates 
containing G418. Loss of ICORE would lead to combined 5-FOA resistance and G418 
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sensitivity (see Figure 1). The colonies unable to grow on G418 are selected from the 
corresponding position in the YPDA plate replicas, purified and tested using colony PCR to 
amplify the targeted locus. Sanger sequencing is used to check the correctness of the inserts. 
Hence, with this approach single or multiple base variants of consensus TF binding sites are 
integrated in yeast to evaluate their transcriptional strengths in the same chromatin locus 
without any alterations in the nearby minimal promoter/reporter (pcyc1-LUC) or other 
genomic regions (11). Besides this genome engineering approach, another feature that can 
assimilate the use of yeast cells for transcription assay to that of an in vivo test tube, is the 
availability of tightly regulated promoter systems for tuneable expression of the desired 
human transcription factors. Hence, a matrix of analysis can be performed where the only 
variables are TF protein amount and the nature of its cognate binding in a completely isogenic 
system (24). As mentioned above, this experimental workflow is enabled also by the 
conservation of basic components of the transcription machinery between yeast and mammals 
that allows human TFs to act as transcription factors in yeast (25). While the basic set-up of 
the experimental system focuses on aspects of cis-regulation, including the impact of TF 
mutations and RE sequence variants, attempts have been made to adapt yeast-based 
transcription assay to screen for small molecules targeting human TFs (26). 
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Figure 1: Delitto perfetto mediated integration of synthetic oligonucleotide (carrying p53/NF-кB 
REs) in yeast chromosome. (A) The yLFM-ICORE yeast strain is transformed with 80nt long 
oligonucleotide carrying an RE of interest. The pre-integrated ICORE cassette is excised and replaced 
with the desired oligo DNA through homologous recombination mediated by 30nt homology arms. 
The ICORE replaced strain becomes G418 sensitive and 5 FOA resistant. (B) Yeast serving as an in 
vivo test tube to quantify RE transactivation specificity. The modified yLFM-RE yeast strain is 
transformed with galactose inducible p53 or NF-кB expression vectors. The transcriptional strength 
and specificity of REs is determined comparing the differences in Firefly luciferase activity. 
Transformed yeast-RE strains are cultured with or without galactose for different time points in a 96-
well round-bottom plate. Luciferase activity is measured by transferring in white 384-well plates 10ul 
of cell culture and permeabilizing cells to the luciferase substrate by adding the same volume of lysis 
buffer (see results section for more details).  
Oligo 
Oligo 
A 
B 
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The tumor suppressor p53 and its isoforms 
More than 35 years ago, p53 protein was reported as an oncogene in cancer but a decade later 
it was realized that the original clone was a mutated version of the protein and the function of 
wild type p53 was redefined as that of a tumour suppressor and subsequently revealed to be 
largely dependent on sequence-specific DNA binding activity and a role in transcriptional 
modulation (27-31). Further studies, continuing to this day have revealed p53 as a master gene 
of cellular responses to an impressively wide array of signalling pathway, regulating an 
extensive network of target genes resulting in the modulation of cell cycle arrest, apoptosis 
and DNA repair, from which the honorary title of “guardian of the genome” has been coined 
(32-35). More recently, p53 functions has been linked to other cellular responses including 
differentiation, tissue regeneration, senescence, carbon and lipid metabolism, inflammation, 
ferroptosis and post-apoptosis (36-39). 
The tumour suppressor p53 shows a high frequency of mutations in a majority of cancer 
types, with a prevalence of missense mutations causing aberrant expression of a protein that in 
some cases exhibits gain-of-function, oncogene-like phenotypes and can lead to a highly 
dysregulated response gene network (40). The discovery of germline p53 mutations resulting 
in high penetrance cancer predisposition syndromes (Li-Fraumeni, Li-Fraumeni-like) was 
very important to establish p53 as a tumour suppressor gene (41). More than 200 different p53 
missense mutations have been identified in the germline that when analysed with transcription 
assays, also in yeast, revealed a range of functional alterations that could be linked to different 
clinical features (25). This led to the proposition that not all p53 mutants expressed in cancer 
possess the same impact and potential prognostic value (12). 
Various p53 mutants acquire oncogenic properties leading to deleterious outcomes like 
unrectified cell cycle progression, metastasis, angiogenesis and stemness in tumour cells (25, 
42-44). Biochemical studies have established that the p53 protein is functional as a tetramer, 
composed by a dimer of dimers (45). The protein contains transactivation and protein 
interaction domains in the amino terminus, a large DNA binding domain with 
immunoglobulin-like fold and a tetramerization and regulatory domain at the carboxy 
terminus (46-48). 
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Many missense mutations cause amino acid substitutions in the p53 DNA binding domain of 
the protein preventing it from binding specific DNA sequences to modulate target expression 
(49). Deletion of the entire carboxyl terminal leads to inability to form p53 tetramers, while 
deletion of just the regulatory domain leads to an apparent slight over-activation of p53 (50). 
Deletions of the N-terminal domains can lead to complete or partial loss of transactivation 
ability (51). The vast majority of p53 mutations in cancer occur in the DNA binding domain. 
Depending on the stress and in a context-dependent manner, p53 regulates downstream targets 
at the transcriptional, post transcriptional and translational level (52). The complexity of p53 
functions in maintaining genome stability and cell homeostasis further increased with the 
identification of p53 isoforms expressed in a tissue specific manner, resulting from an 
alternative promoter usage, alternative translation initiation and alternative splicing (53, 54). 
So far 9 p53 isoforms have been identified (see Figure 2) from the alternate splicing of full 
length p53α transcript (p53β, p53Y, ∆ 40 α, β, Y and ∆ p53) or the usage of the alternative 
promoter in intron four (∆133 α, β, Y) (55). Most of these isoforms lack the transactivation 
domain; some also do not maintain the sequence-specific DNA binding activity of full-length 
p53 but can inhibit p53α function, in part through hetero-tetramerization. The functional role 
of unbalanced expression of p53 isoforms still needs to be fully characterized, but critical 
roles are emerging for example in senescence, neurodegenerative diseases, premature aging 
and embryo malformations (54). Notably, p53 regulates the transcription of its own isoforms 
Δ133p53 (56, 57). Apparently, another isoform of p53 called Ψ (psi) which stays extra nuclear 
due to lack of nuclear localization sequence enhances the motility and invasive capacity of 
cells and lacks the transcriptional abilities (58).  
 
p53 regulating circuit board 
Cells in homeostasis maintain p53 at very low levels through its constitutive proteosomal 
degradation by various negative regulators, of which the ubiquitin ligase MDM2 is the most 
prominent (59). Intrinsic and extrinsic stress signals leading to loss of fidelity in chromosomal 
segregation, DNA replication stress or double stand DNA breaks stabilize p53 levels in cells. 
This stabilization is achieved mainly by post-translational changes inhibiting the interaction 
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between p53 and its regulators. DNA damaging responses inhibit the interactions between p53 
protein and its negative regulators like MDM-2, Cop-1, Pirh-2, delta N p73, cyclin G, Wip-1 
and Siah-1 in a specific manner to activate the p53 pathways (60). Many of these negative 
regulators are under the transcriptional control of p53, thus mainting negative feedback loops 
to keep p53 at low levels. On the contrary, p53 controlled genes like PTEN, AKT, p14/19ARF 
maintain a positive feedback loop to upregulate p53 levels in the cell. 
Various strategies are implemented to activate p53 or restore mutant p53 activity in cells as 
cancer therapy. The non genotoxic drug Nutlin-3A has emerged as one of the most efficient 
small molecule activator of p53. It relieves p53 from its negative regulator MDM2. Other than 
the activation of wild type p53, reversion of p53 mutant forms into a transcriptionally active 
state has also be extensively attempted and considered a valuable treatment strategy (61). In 
this context, PRIMA-1 has emerged as a drug that can covalently bind p53 mutants (R273H 
and R175H) to restore at least in part their function in vitro as well as in vivo (62, 63). Also, 
mutant p53 Y220C is targetable via compounds PK083 and PK7088, identified through a 
rational, structure-based approach (64, 65). More recently, the Y220C mutant p53 activating 
compund has been reported to act also as an inhibitor of heat shock protein Hsp90 (66). 
Another group has reported tryptophanol derived oxazoloisoindolinone SLMP53-1 as mutant 
p53 activators (67). 
Other than activation and stabilization of p53, various post translational modifications of p53 
protein alter its trancriptional specificites. Modifications at particular p53 amino acid residues 
such as phosphorylation, acetylation and methylation dictate the p53 response to diverse 
cellular signals and help determine its physiological activities (68, 69) (44, 50). Six acetyl 
transferases are identified so far which modify p53 at the C terminus or its central DNA 
binding domain to increases p53 protein stability, binding to low affinity promoters, 
association with other proteins, antiviral activities etc. (70). The six acetyl transferases can be 
divided into two groups, one comprising p300/CBP/PCAF the other Tip60/MOF/MOZ (see 
later section for more information on TIP60 and MOF). There are eight main acetylation sites 
on human p53 (K120, 164, 370, 372, 373, 381, 382 and 386) and changes of the first three 
sites from Lysine to Arginine strongly impact on p53 transcriptional function preventing cell 
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cycle arrest and/or canonical apoptosis, but still resulting in tumor suppression in a mouse 
model (71).  
 
Figure 2: Gene Structure and alternative splicing of TA p53α transcript. (a) p53 gene structure 
schematics, alternative splicing and internal promoter are shown (b) Transcripts from promoter P1 
give rise to p53 protein isoforms α, β and γ conserved at N-terminal. Δ40p53 protein isoforms have 
lost the conserved N-terminal domain of transactivation but still contain part of the transactivation 
domain. The internal promoter P2 in intron 4 transcribes Δ133 isoforms. (53) 
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p53: Sequence specificity as a transcription factor  
The p53 protein belongs to the class of highly sequence-specific transcription factors. It 
recognizes a palindromic RE of 10 nucleotides (RRRCWWGYYY). Two such motifs, 
providing interaction with one p53 dimer, can be either adjacent or spaced apart by up to 13 or 
in some experiments up to ~20 nucleotides without large changes in DNA binding affinity 
measured in vitro with naked DNA (72). However, more recent studies, using either longer 
DNA molecules in vitro or measuring p53 occupancy in chromatin using ChIP assays, 
revealed a preference for adjacent decameric motifs (73). Further, results from functional 
assays in various systems and competitive DNA binding assays in solution consistently 
showed higher affinity and transactivation for REs that do not have spacer between the two 
decameric motifs (74). At the same time, additional variants of the p53 RE have been 
identified and grouped as non-canonical REs (72, 75, 76). These consist of ¾ sites (one 
decamer plus an adjacent half decamer) or half sites (decamers) and can also mediate p53 
binding and gene responsiveness (77) (see below for further details). In terms of location in 
the genome, p53 REs are generally embedded in the promoter or proximal enhancer regions of 
established p53 target genes (78), but there are many examples of REs in intronic regions, in 
distal enhancers, in super-enhancers (79), in repetitive elements (80) and it has been proposed 
that besides mediating transcriptional regulation, p53 REs may serve as chromatin 
accessibility factors contributing to p53-mediated genome stability (81) 
Since the consensus p53 RE motif is highly degenerate (RRRCWWGYYY)2, it is implied that 
individual REs can differ in sequence by one to several nucleotides, potentially impacting on 
DNA binding affinity. In addition, well-established p53 REs often contain up to three non-
consensus bases –herein defined as mismatches- that can further contribute to differences in 
DNA binding affinity. Hence it has been hypothesized that the specific nature of the p53 RE 
can directly impact on transactivation specificity to the point that specific types of REs would 
have been selected in the promoters of p53 target genes implicated in different biological 
responses, for example cell cycle arrest or apoptosis (82, 83).  
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Indeed the nucleotide mismatches in CWWG core domain or the flanking purines (RRR) and 
pyrimidines (YYY) alter the RE transcriptional specificity depending on the expression level 
of p53 protein. Hundreds of p53 target genes have been identified in the human genome 
(among which p21, MDM2, BAX, PUMA, GADD45, KILLER, FAS are among the best 
characterized) (72, 76), and indeed virtually all p53 REs are non-identical in sequence and it 
appears that high affinity consensus motifs have been negatively selected in evolution, and 
also that there has been significant evolutionary divergence among p53 REs from different 
species (84, 85). Various bioinformatics tools are dedicated to specifically scan regulatory 
regions in genomes to identify p53 REs. The p53 MH algorithm developed by J. Hoh et al 
ranks putative p53 REs by allocating a score as percent similarity to the consensus sequence 
using a position weight matrix. Out of around 4000 genes registered for the p53 binding sites 
availability, only 25 genes show perfect match with the consensus p53 recognition DNA 
binding site. 
One of the first study to map p53 occupancy on a genome scale combined chromatin 
immunoprecipitation ChIP and paired-end ditag (PET) sequencing strategy and revealed 
specific p53 binding enriched loci in the human genome discovering 98 new p53 binding sites 
(86) and annotating a total of ~500 p53 bound sites. By treating U2OS cells (osteosarcoma 
tumour cells) with two anti-cancer drugs, Doxorubicin and Nutlin-3A, differential selectivity 
of p53 expression and binding patterns through ChIP and high throughput sequencing 
methodology was established, identifying 149 new p53 target sites in human genome. 
Validation of weak to strong p53 REs suggested p53 binding to DNA and relative 
transactivation as two independent events (87).  
As summarized above, yeast-based functional assays have been extensively used to compare 
the transactivation potential of p53 REs. Yeast-based transactivation assays confirm that 
binding affinity of REs have no significant correlation with the p53 mediated transactivation 
potentials. Yeast based functional ranking of 26 different p53 REs, out of which four were 
artificial REs, reveal differential impact of alternations in CWWG core on transactivation 
potentials in a p53 concentration-dependent manner, establishing the CATG core as the most 
transcriptionally active motif. As presented above, the construction of many variants of the 
p53 REs at the same genome location was greatly facilitated by the delitto perfetto approach 
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(23). Furthermore, the functional assay has been exploited to test the most representative p53 
missense mutations including most of those found in the germline (12). The results 
established different classes of p53 mutants; besides loss of function mutations, various p53 
mutants, especially when expressed at high concentration showed wild type like 
transactivation potential, while others were partially functional and even a small group of 
mutants with increased function were identified –see next section for more details- (8, 11, 19, 
88-93). More recently, all the information on the sequence features of p53 REs and resulting 
transactivation potential were coded in a pattern search algorithm, called p53 REtriever, that 
maps and then ranks canonical p53 full sites as well as non canonical half sites and ¾
 
sites 
according to their predicted transactivation potentials. The in silico predicted functional and 
non-functional REs were cross-referenced with data from ChIP-seq, ChIP-exo, expression, 
and various literature data sources (94). Taken together, all the studies on p53 binding sites 
establish p53 as a highly pleiotropic master regulator of a vast transcriptional network.  
As mentioned above, besides the remarkable degeneration of p53 REs, another unexpected 
finding has been the relatively high evolutionary divergence of these sequences. A widespread 
turnover of p53 binding sites through the period of 500 million years has been captured by a 
study on comparative analysis of functional v/s sequence homology of 47 p53 REs 
corresponding to 38 genes in a group of 14 species. Also, yeast-based transactivation assays 
performed with p53 protein isolated from six chordate species provides an outlook of 
phenotypic divergence or convergence of p53 as a sequence specific transcription factor (85). 
REs tested with species-specific p53 protein exhibited relative transactivation differences 
represented as their unique functional fingerprints. Attempts have been made to evaluate the 
temperature sensitivity of species-specific p53 as TF and to exploit chimeric p53 constructs in 
understanding the conservation of p53 transactivation specificity or lack thereof (95). For 
example, PRODH genes carry various putative p53 REs in promoter or intronic regions. 
However, transactivation assays show negligible conservation of functional p53 REs within 
PRODH family revealing PRODH2 not as a direct p53 target (96). The conservation of p53 
REs is also in effect to features like transposing elements and nucleosome accessibility. 
Weaker p53 REs are more conserved and found in chromatin accessible regions and p53 
occupancy and PWM scores are negatively correlated with the evolutionary conservation and 
chromatic accessibility (97). 
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Non canonical p53 binding sites such as half sites or ¾ sites are functional depending on the 
intracellular p53 levels enhancing the dynamicity of p53-mediated regulatory networks. 
Among the p53 half site (decamer) core (CWWG) variants, CATG show the highest 
transactivation potential, followed by CTTG, CAAG and CTAG. The spacer elements 
separating p53 binding sites have been demonstrated to have variable impacts on the 
transactivation potential depending on the length of the spacer and strength of the REs. 
Typically, a spacer element between two half sites has been shown to decrease p53-mediated 
transactivation potential, but non canonical p53 REs can work synergistically upon the 
presence of a 17nt long spacer between them (77). The transactivation potential of p21 RE 
decreases depending on the number of nucleotides separating the two half sites. A two-
nucleotide separation of p21 half sites already drastically reduces the activity of the RE. The 
organization of REs in the genome affects the accessibility of binding sites and their 
interactions with the nearby cis-elements. Variably organized p53 binding sites in the genome 
exhibit cis-cis interactions and non canonical p53 sites can synergize with other half sites such 
as Estrogen Receptor (ER) ½ sites and, upon estradiol and p53-activating treatments, lead to 
concerted activation of a target gene (98). Functional single nucleotide polymorphs (SNPs) 
can also have a significant impact on response elements towards p53 occupancy causing 
genetic diversity in p53 regulatory network (99). All together, these studies reveal a collective 
impact of DNA elements and their variations on DNA structure and transcriptional outcomes 
that can be dissected and studied in details using systems in yeast.  
 
Mutant p53 as tool to study RE-dependent transactivation specificity 
 
As noted above, p53 missense mutations are abundant in cancer and, depending on the amino 
acid substitution or deletion, the protein shows variably reduced transactivation capacities in a 
RE specific manner. Depending on the site of mutation, the ability of p53 to form a tetramer, 
bind the DNA motif or ability to transactivate is abrogated. Yeast-based transactivation assays 
illustrate the promoter selectivity of distinct L1 loop p53 mutants. C–terminal deletants  
revealed that mutants with loss of tetramer forming abilities cannot transactivate while 
deletion of the regulatory region, (after amino acid 368) results in reduced transactivation 
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potential leading to moderate activation of transcription from half or quarter REs at high 
levels of mutant protein expression. Certain mutations in the DNA binding domain of p53 
lead to super-transactivation phenotype. Potentially, supertrans mutants that are not impeded 
by dominant negative mutations in cells could be very useful for cancer therapy if identified 
with stronger tumor suppressor abilities (10, 77, 93).   
 
Structural properties of DNA can also influence the transcriptional decisions giving relevance 
to aspects like shape and geometry of DNA comprising a binding site. For example, the noted 
difference in transactivation and DNA binding affinity associated with consensus variants of 
the CWWG core (e.g. CATG>CTAG) cannot be directly explained by altered contacts 
between the p53 DNA binding domain and DNA as the protein does not make base read-out 
at those positions, according to most structure studies. In vitro experiments proposed that 
DNA bending might contribute to the specific features of CATG p53 REs (100). Other 
biophysical parameters have been considered to characterize and correlate sequence and 
functional properties of p53 REs. Genes containing low cooperativity p53 REs are enriched 
for cell cycle functions while genes controlled through high cooperativity p53 REs are 
enriched for apoptotic function (101).  
A binding site can be denoted as structurally rigid or flexible and hence affecting the binding 
of p53 tetramer or dimer based on the identity of nucleotides forming it. The torsional 
properties of the p53 binding core (CWWG) and pur/pyr (GGG/CCC) flanks impart 
transactivation strength to an RE. A stretch of three guanines (GGG) on the 5’ end of p53 RE 
is torsionally flexible and enhances the responsiveness of binding sites. A torsionally flexible 
DNA sequence has a high transactivation potential even at low p53 levels due to low 
dissociation rates of the protein from DNA binding site. The CATG core remains the most 
transcriptionally active binding site even at low levels of p53 and binds p53 molecules with 
low cooperativity as well, meaning that p53 dimers can be independently recruited at such 
sites. On the contrary CAAG and in CTAG motifs exhibit high cooperativity and tetramer-
dependent p53 binding, but lower transactivation potential (102-104).  
 
UNIVERSITY OF TRENTO                                                                      PhD Thesis (2014-2015)   Vasundhara Sharma 
CIBIO                                                                             “Cis and Trans, p53 and NF-кB rules of Transactivation”  Tutor: Alberto Inga 
25 
 
Siblings of p53: p63 and p73 
p63 and p73 are paralogs of p53 and share structural and functional homology (Figure 3). The 
p63 and p73 proteins are mainly involved in developmental and cell differentiation processes 
but they share the ability to target at least some of the p53 responsive promoters. p63 and p73 
are also tetrameric transcription factors and heterotetramers can be formed with impacts on 
target site interaction (105, 106). It has been demonstrated that a vast number of genome-wide 
p53 target sites can also be bound by overexpressed p63 and p73 in vivo (73). Also yeast-
based assays reveal that p53, p63 and p73 exhibit a similar, but not identical transactivation 
profile (74). Various splice variants of p63 and p73 also exist (see Figure 4 and 5). A yeast-
based study elucidates the impact of p53 mutants on the transactivation abilities of p73β-
isoform (transcriptionally active) signifying the presence of functional interplay between p53, 
p63 and p73 in their mutant or WT forms. The relative transactivation abilities of p63 and p73 
isoforms evaluated using yeast revealed that ∆N-P63α and TA-P63α isoforms showed 
significant differences in terms of transactivation capacity and specificity when tested with an 
array of REs (107). The same phenotype was not observed for p73. The DNA binding 
domains of the three proteins has the highest conservation level. For example, corresponding 
p73 mutations in the L1 loop exhibited equivalent changes in transactivation specificity seen 
with p53 mutants (93).  
 
Figure 3: Structural conservation between p53, p63 and p73. p63 and p73 are 25% and 29% 
conserved at the N-terminal Transactivation domain with respect to p53, respectively. The DNA 
binding domain shows 65% and 63% conservation of p63 and p73. The oligomerization domain is 
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35% and 38% conserved for the proteins relative to p53 as shown. (source) 
http://p53.free.fr/p53_info/p73_p63.html   
 
Figure 4: p63 gene transcripts: The transcription from promoter P1 at intron 1 generates 
transactivation domain carrying isoforms. The alternative splicing form intron 10 till 14 forms either β 
or γ isofoms.  The transcription from promoter 2 generated N-terminal deleted isoforms. (Source): 
http://p53.free.fr/p53_info/p73_p63.html 
 
Figure 5: p73 gene transcripts: p73 α transcripts arising from promoter 2 are N-terminal deleted 
unlike those from   promoter 1 which carry the TA domain. Alternative splicing from intron 10 till 12 
generates five different isoforms β,γ,δ,ε or ζ as shown. (Source): 
http://p53.free.fr/p53_info/p73_p63.html 
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NF-кB family of transcription factors 
NF-кB proteins are highly dysregulated in cancer and one of the central players of pro-
inflammatory responses in tumours (108).  Constitutive expression or lack of expression of 
NF-кB pathway proteins lead to muscular and neurodegenerative diseases or diabetes (type I 
and II). NF-кB is constitutively expressed in cells and does not require new protein synthesis 
upon stimuli to activate a response. It exists as an inactive complex kept in the cytoplasm by 
the interaction with an inhibitory cofactor, IкB. Such inhibition is relieved by post-
translational regulation of IкB that occurs in response to specific stimuli, such as the exposure 
of cells to inflammatory cytokines, such as TNFα, or molecules associated with pathogen 
infections (Pathogen Associated Molecular Patterns, PAMPS) and is mediated by the IKK 
complex (IкB kinase). Interactions of these extracellular factors with their receptors (TNFRSF 
or TLRs) (109) activates signal transduction pathways leading to IкB phosphorylation and 
degradation. NF-kB is activated through canonical as well as non canonical pathways (see Fig 
6) enabling the protein to relocate to the nucleus to act as a sequence-specific TF (110-115). 
NF-кB family comprises 5 subunits p50, p52, p65 (REL A), c-rel and relB which form either 
homo or hetero-dimers to recognize a loosely consensus RE of 10-11 nucleotides “5’-
GGGRNWYYCC-3’ ” (R = purine, N = any nucleotide= adenine or thymine, and Y = 
pyrimidine) (116, 117). Some atypical pathways are also known to activate NF-кB in response 
to stimuli such as genotoxic stress, UV and hypoxia with or without IKK involvement (111). 
ChIP-seq data suggest that >1000 genes can be regulated by NF-кB proteins such as 
chemokines, immunoreceptors, stress response genes, regulators of apoptosis, growth factors 
etc. Approximately 1.5 x 10
5 
NF-kB binding sites have been mapped in the human genome 
(118). A detailed description of NF-кB activators, inhibitors, diseases and target genes can be 
found at http://www.bu.edu/nf-kb/. The NF-кB family proteins comprise a structurally 
conserved Rel homology domain (RHD) conferring DNA binding activity. The RHD is 
formed of ~300 amino acids allowing the dimerization of the subunits and includes a nuclear 
localization sequence which binds to the IкB protein. Variability exists within the family 
members at the C-terminus. The transactivation domain (TAD) is localized in the C-terminal 
region and is not shared by all family members (see Table 1) Mutations in NF-кB proteins in 
mouse models are associated with various physiological lethal phenotypes (119-121). The 
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interplay between the NF-кB family members leads to early or late responsiveness of the 
target genes in genomic context. Various homo- or hetero-dimers are reported to act in 
cellular context but p50/p65 complex is the most active and abundant heterodimer found in 
cells. p50 and p52 proteins lack a transactivation domain and hence cannot function as a 
homodimers, requiring additional cofactors like BCL3 and BCL6 to transactivate the targets 
(122, 123).  
 
Various studies established that the nucleotides in a RE define the binding affinities of NF-кB 
subunits and that even a single nucleotide variation in a NF-кB RE can profoundly alter the 
transactivation capacity of NF-кB proteins (124, 125). The transactivation capacity of a NF-
кB protein has positive correlation with the RE binding affinity (126, 127). Various non-
canonical NF-кB binding sites have been identified using techniques such as gel-shifts, ChIP-
seq and Selex specifically focussing on NF-кB protein REL A (p65) (128). The degeneracy in 
NF-кB consensus RE provides opportunity for complex cis-regulation, transactivation 
specificity and gene expression tuning (129). Many transcription factors, like Sp1 or NFAT 
are reported to function with NF-кB conferring further plasticity (130). Table 1 summarizes 
concisely features of the biology of NF-кB family members.  
As for the case of p53, there is no clear NF-кB homolog in yeast, although the RTG family of 
proteins (RTG1, RTG2 and RTG3) involved in yeast mitochondrial retrograde pathway has 
been proposed to share structural similarity with NF-кB (131).  
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        .           
Figure 6: Canonical and non-canonical pathways for NF-κB activation. The canonical pathway 
(left side) leads to the activation of RelA-p50 heterodimers. After stimuli such as TNFα or IL-1, the 
IKK complex containing NEMO, IKKα and IKKβ phosphorylates IκBα on Ser32 and Ser36, inducing 
ubiquitination and proteasomal degradation of IκBα, thus releasing RelA-p50 dimers, which then 
translocate to the nucleus to regulate the target gene transcription. The non-canonical pathway (right 
side) is responsible for p100 processing and p52 activation. Following stimuli by CD40 or LPS, NIK 
phosphorylates the IKKα complex. These kinases then phosphorylate p100 on Ser866 and Ser870, 
leading to its ubiquitination and p100 processing into p52. p52, forming a dimer with RelB, translocate 
to the nucleus and then can regulate the transcription of target genes. Other combinations of NF-κB 
dimerization than RelA-p50 or RelB-p52 are also possible (6). 
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Family 
member 
Active form/ 
dimer 
In vivo expression, 
abundance and 
localization 
Presence of 
Transactivation 
domain (TAD) 
Impact of  Loss of 
Function 
RelA/ 
p65 
Dimerizes with p50, 
most abundant 
heterodimer and 
transcription 
activator 
Major and most crucial 
NF-κB subunit, highly 
abundant as 
heterodimer with p50  
Yes Severe phenotypes 
such as embryonic 
lethality observed 
in mice 
p50 
 
Forms a self-dimer 
(p50/p50) involved 
in repression of p65 
activity 
Nearly ubiquitously 
expressed 
No Defect in their 
ability to generate a 
humoral immune 
response 
p52 
 
Forms transcription 
activating complex 
with bcl3 
Expressed mainly in 
stomach epithelium and 
immune cells 
No Slight defect in the 
splenic and lymph 
node architecture 
c-Rel Dimerizes with p50 
and p52 both 
More gene specific 
expression and 
responsiveness 
Yes B cell defect like 
p50.  
Rel B Dimerizes with p52 Localized in dendritic 
cells and lymphocytes 
Yes defects in both 
acquired and innate 
immune response 
Table 1: Features of five NF-κB subunits and effect of their loss in cells. The table summarizes the 
expression, localization and dimerization of five NF-κB subunits and the effect of their loss of function in 
cells.  
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MATERIALS AND METHODS 
Materials and Methods for the NF-кB project are included in the published manuscript which 
is presented at the end of the results section. This materials and methods section refers to the 
procedures employed for the unpublished work described in the Results sections 
 
Construction of yeast reporter strains containing p53 Response Elements regulating the 
expression of the Firefly cDNA 
A panel of isogenic yeast reporter strains containing either single copies of the decameric p53 
RE (i.e. half site), or a full site consisting of two adjacent identical half sites were constructed 
using single strand oligonucleotides (synthesized by Eurofins MWG Operon, Ebersberg, 
Germany), targeted at a modified chromosomal XV locus containing a minimal CYC1 
promoter driving the expression of the Firefly luciferase cDNA. These experiments were 
developed following a previously published approach (19, 85) that is an adaptation of the 
“delitto perfetto” system for in-vivo site-directed mutagenesis (23, 132) and exploited the 
yLFM-ICORE strain (19, 85, 99). The protocol utilizes oligonucleotides that contain a desired 
p53 RE, flanked by two short (30nt) homology tails to direct them to the chosen integration 
site, and exploits a triple-marker cassette (ICORE) positioned in the yLFM-ICORE strain near 
the CYC1 promoter on chromosome XV (ADE2 gene location). The cassette contains a 
counter-selectable gene (URA3), a reporter gene (kanMX4), and the I-SceI homing 
endonuclease along with its unique 18nt recognition site. Expression of I-SceI is controlled by 
the GAL1 promoter and leads to the induction of a unique double-strand break (DSB) at the 
site where the cassette is cloned, which in turn leads to high efficiency homologous 
recombination and integration of the oligonucleotide. The desired oligonucleotides are 
transformed into yeast after culturing cells for 4 hours in galactose-containing medium to 
induce I-SceI expression and the induction of the DSB. The homology tails correspond to the 
yeast chromosomal sequences flanking the ICORE integration site, while the desired p53 RE 
is at the centre of the oligonucleotide. Oligonucleotide targeting events are selected exploiting 
the counter-selectable marker, by plating transformants on medium containing 5-fluorotic acid 
(1g/L). Colonies appearing on such plates after 3-4 days of incubation at 30°C are streaked or 
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patched onto rich YPDA plates and then replica plated on both YPDA and YPDA-G418 
(0.4mg/ml) plates. Loss of the reporter cassette is assessed by the lack of growth on YPDA-
G418. Correct reporter strains’ construction is the confirmed by colony PCR across the 
engineered chromosomal region (22), followed by DNA direct sequencing (BMR Genomics, 
Padua, Italy). 
 
Yeast transformation and luciferase assays 
The newly constructed yLFM-p53-RE and yLFM p21 RE strains (see Figure 7 and Table 4 for 
the list) were transformed with the pLS89 (93) or pTSG-hp53 (92) p53 expression vector 
using standard LiAc protocol followed by heat shock (133). Both vectors are tryptophan 
(TRP1) selectable. Inducible expression in yeast of p53 WT protein was achieved exploiting 
GAL promoters (galactose inducible) (85). Transformants were then processed for the 
miniaturized protocol of the luciferase assay (19, 134). Transformant colonies kept on 
selective glucose plates, lacking tryptophan, were grown for 16 hours, unless otherwise stated, 
in synthetic tryptophan-deficient liquid media containing raffinose (2%) with or without 
different concentrations of galactose, which serves as inducer of the GAL1 promoter driving 
the expression of the p53 protein. Luciferase activity was measured using the Bright Glo 
Luciferase assay kit (Promega, Milan, Italy) and expressed either as relative light units (RLU) 
normalized to optical density (λ=600 nm), subtracting the luminescence obtained by the cells 
transformed with an empty vector (pRS314) in each reporter strain, or expressed as fold 
induction over the empty vector. Experiments included four to seven biological repeats and 
the results were plotted as mean values and standard errors of the mean. 
 
Cloning of p53 binding motifs in the pGL4.26 mammalian reporter vector  
Nine of the half site and full site p53 REs tested in yeast were further tested in the H1299 and 
A549 human cell lines. To this aim, the RE sequences were cloned upstream of the promoter 
driving Firefly luciferase gene expression within the commercial pGL4.26 vector (Promega), 
using a pair of complementary oligonucleotides ligated into KpnI/XhoI double-digested 
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plasmid DNA. A unique NdeI restriction site was included in the oligonucleotides 5’ to the 
REs to facilitate the identification of ligation products. Plasmids were purified and sequenced 
across the modified region.  
 
Dual luciferase assays in human cells 
The lung cancer derived A549 and H1299 cells were cultured in RPMI media supplemented 
with 10% FBS 2mM L-Glutamine and 1X Penicillin/ Streptomycin mixture (Pen/Strep). 
Relevant to our aim, H1299 are p53 null while A549 express wild type p53 protein that can be 
activated by genotoxic stress or small molecules inhibiting MDM2::p53 interactions. For gene 
reporter assays, H1299 and A549 cells were transiently transfected at ~80% confluence using 
TransIT-LT1 Transfection Reagent (Mirus) and Lipofectamine LTX (Invitrogen), 
respectively, in a 24-well plate. 250 ng of the newly constructed pGL4.26 reporters and 50 ng 
of the pRL-SV40 control luciferase vector were used. H1299 cells being null for p53 
expression, the transfection mix also contained different amounts of a p53 expressing plasmid 
(CMV-based) and/ or an empty control plasmid always maintaining the total concentration of 
500 ng DNA in each well. Each experiment was performed in triplicates and a total of 4 
biological replicates were used for analysis. A549 cells were treated with Doxorubicin (1.5 
µM or 3µM) and Nutlin-3A (10 µM) to activate p53. Dual luciferase assay was performed 30 
hours post transfection for H1299 using dual luciferase kit (Promega) following the 
manufacturer’s protocol whereas in A549 cells, p53-activating treatments were started 24 
hours post transfection and the luciferase activity was captured at 8, 12 or 16 hours post 
treatment. 
 
Construction of pRS314-RGF bidirectional reporters carrying p53 REs 
with their genomic or synthetic flanking sequence 
A bidirectional reporter plasmid pRS314-RGF containing the 600nt bidirectional, galactose-
inducible GAL1,10 promoter transcribing both Firefly and Renilla Luciferase cDNAs, 
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respectively, from GAL1 and GAL10 side, was available in the laboratory. The plasmid is 
tryptophan selective (TRP1) allowing the transformants to grow in tryptophan-lacking media. 
The GAL1,10 promoter was further modified by introducing p53 REs flanked by 20-nt 
sequences from each side, exploiting a unique Age I site located at the exact centre of the 
promoter sequence. To accomplish the integration, sixty-six nucleotides long pairs of 
complementary oligonucleotides (carrying p53 REs along with contiguous natural or synthetic 
genomic flanks) were annealed to generate dsDNA with Age I compatible ends that was 
ligated in Age I digested pRS314-RGF plasmid. The ligation mixes were transformed in DH5-
alpha competent E. coli cells using the KCM protocol and correct clones containing the 
oligonucleotides in the desired orientation were identified from miniprep plasmid DNA 
preparations using restriction digestion tests and PCR with orientation specific primer pairs.  
The orientation and correct sequence of selected clones was confirmed by Sanger sequencing. 
 
Yeast transformation of bidirectional reporters and measurement of Dual 
Luciferase activity 
pRS314-RGF (TRP1 marked) plasmid containing p53 REs and a p53 expression vector 
(pLLS-p53, LEU2 marked) (85) were co-transformed in the yIG-397 yeast strain using 
standard LiAc protocol (133). Transformants were selected and purified using leucine and 
tryptophan double drop-out media. The luciferase assay was performed essentially as 
summarized above except that to measure both Firefly and Renilla Luciferase activities the 
Dual Luciferase assay kit (Promega, Milan, Italy) was utilized. Results were expressed either 
as Firefly or Renilla relative light units (RLU) normalized to optical density (600 nm), 
subtracting the luminescence obtained by the cells transformed with an empty p53 expression 
vector and each bidirectional reporter plasmid, or as fold induction over an empty pRS314-
RGF vector in cells expressing p53. Experiments included four to seven biological repeats and 
the results were plotted as mean values and standard errors of the mean. 
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Firefly and Renilla promoter inversion in pRS314-RG10F plasmid 
As an additional control, the orientation of the GAL1,10 bidirectional promoter was reversed 
inside the plasmid to test a potential impact of promoter biasness on Firefly and Renilla 
Luciferase transcription. In fact, we noticed that, depending on the amount of galactose in the 
medium and time-point, the induction of GAL1 and GAL10 was not equivalent, with GAL1 
being significantly more active than GAL10 (see Result section). The promoter inversion was 
achieved by exploiting two Nco I sites present at both sides of the promoter and overlapping 
with Firefly and Renilla ATG sites. pRS314-RGF plasmids were restricted with Nco I and 
products resolved on in 1% agarose gel. The plasmid backbone and the ~660 nucleotide long 
promoter fragments were gel extracted and purified using a commercial kit (Qiagen, gel 
extraction kit). The two bands were re-ligated and transformed in DH5-alpha cells followed 
by screening of inverse orientation clones by orientation PCR with the help of appropriate pair 
of primers.  The new constructs now expressing Firefly from GAL10 and Renilla from the 
relatively stronger GAL1 promoter were also tested for their dual Luciferase activity as 
described above.   
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RESULTS 
Part A. p53 studies 
1. “within-RE” sequence code for transactivation capacity 
Impact of consensus changes within the canonical or half site p53 RE on 
transactivation 
We attempted to evaluate p53 transactivation potential towards specific variants of the 
consensus p53 RE using defined functional assays in yeast and human cells. The same p53 
REs were used for co-crystallization studies with the human p53 DNA binding domain 
(Hector Viadiu, UNAM, Mexico), and they represent ad-hoc variations meant to probe the 
impact of specific changes in the CWWG core and flanking purine or pyrimidines. We 
compared both half sites (consensus sequence R1R2R3C4W5W6G7Y8Y9Y10 –see Introduction-) 
and full sites comprising two adjacent half sites without spacer. For these experiments first we 
took advantage of the yeast-based assay that exploits variable expression of p53 (under GAL1 
promoter) and single copy integration of the p53 REs upstream of a minimal cyc1 promoter at 
a modified ADE2 chromosomal location (22). Reporter gene assays were also developed in 
p53 null H1299 and in p53 wild type A549 human cells using a plasmid reporter system that 
incorporates the desired p53 REs upstream of a minimal promoter. H1299 cells were 
cotransfected with variable amounts of p53 expression plasmids, while A549 cells were 
treated either with doxorubicin or with Nutlin-3A to activate p53 and the level of expression 
of the reporter was measured at different time points after treatment.  
 The list of p53 REs tested in the yeast-based assays is presented in Figure 7, along 
with the relative transactivation measured 16 hours after placing yeast reporter cells in 
galactose-containing medium to activate human p53 expression. In this assay the amount of 
p53 protein is proportional to the amount of galactose (11, 85, 135). Results confirmed the 
expected dramatic difference in transactivation potential between half sites and full sites, the 
former requiring high levels of p53 to show transactivation (Figure 7). Only half sites with 
CATG core led to moderate levels of transactivation at high p53 expression. Consensus 
changes in the purines (i.e. G>A) or pyrimidines (i.e. C>T), symmetric within the half sites, 
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can have an impact on RE responsiveness, depending on their position. While such changes at 
the R3/Y8 adjacent to the core had virtually no impact, the same pair of changes in position 
R2/Y9 nearly abolished transactivation even at high p53 levels, consistent with previous 
observations (85, 135). Also the changes at R1/Y10 had a rather severe negative impact, 
although this position is known to be more variable among well-established p53 REs (136, 
137) and not directly contacted by the protein, according to crystal structure data (103, 138). 
Among full site REs, large differences in transactivation potential were apparent at low p53 
protein levels, while most REs were nearly equally responsive at high p53 levels, with the 
striking exception of the full sites with mismatches at the W5W6 position or with an inversion 
of the R and Y code. The latter results confirm that the W5W6 bases are essential for p53-
dependent transactivation, with TA being the least responsive but only at low p53 levels, even 
though they do not provide any direct contact with the protein and even in the context of the 
highest responsive configuration of Rs and Ys (GGG and CCC with two adjacent half sites). 
Unexpectedly, the asymmetric RE with AAA/CCC flanking the CATG core was highly 
responsive at low and particularly at high p53 levels, while as a half site this sequence was 
weakly responsive, consistent with the negative impact of even a single G>A change.  
 The two most responsive half sites and seven full sites were chosen for the 
experiments in human cells (Table 2). First we tested the p53 null H1299 cells and 
cotransfected them with a human p53 expression vector, or empty vector, (25 and 50 ng), 
along with the Firefly reporter plasmid and a control Renilla Reniformis expression vector. 
Results showed the expected dramatic difference between half-site and full-site 
responsiveness, and confirmed the slightly higher responsiveness when GGG/CCC flanks the 
CATG core in a half site. We also confirmed the lack of responsiveness of a full site RE with 
inverted R and Y code. Transactivation was somewhat proportional to the amount of p53 
expression plasmid transfected, although, unlike the case with yeast, these experiments were 
based on transient transfection and can be influenced by cell-to-cell variability in plasmid 
uptake. Results with full-site REs confirmed the relatively higher responsiveness when 
GGG/CCC flanks the CATG core. The higher responsiveness of AT as W5W6 dinucleotide 
was also confirmed, but the TT motif was equally responsive in the transfection experiments 
with higher levels of p53 expression plasmid. The R1/Y10 had a more severe negative impact 
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compared to yeast, and, consistently, the asymmetric RE with AAA/CCC was not highly 
responsive (Figure 8).  
 The transient transfection experiments were extended to the A549 cells that express 
endogenous wild type p53. Results were compared between mock culture condition, i.e. at the 
basal level of endogenous p53 in those cells in standard culture conditions, or after treating 
them with two different p53-inducing agents: doxorubicin, a genotoxic chemotherapeutic 
molecule that activates the DNA damage response resulting in p53 stabilization and activation 
(107), or Nutlin-3A a small molecule inhibitor of MDM2 (139), considered a non genotoxic 
inducer of p53. Different p53-activating treatments can impact in distinct ways upon p53-
dependent functions due to specific post-translational modifications of p53 protein or due to 
indirect effects (87, 140-142). Since the two treatments also differed in their kinetics of p53 
protein stabilization, the gene reporter assays were performed at different time points and in 
the case of doxorubicin a lower dose was used for the longer time point, which also 
corresponds to longer time after transfection (Figure 9). The main sequence requirements of 
full site REs were confirmed also in A549 and with both treatments. Only the GGG/CCC half 
site (RE 3) showed some responsiveness in this cell line and at the later time point. Most full 
sites were active also in untreated cells and the activity increased with transfection time. 
However, the full site RE with GGG/CCC flanking the CATG core (RE 8) was not the most 
responsive in mock condition nor in treated cells, with the exception of early treatment with 
Nutlin. The two p53-inducing agents led to a similar ranking of full site p53 REs’ 
transactivation at the later time point, when the REs with TT (RE 9) and AA (RE 5) as W5W6 
dinucleotides were the most responsive together with the asymmetric RE with AAA/CCC (RE 
4) sequences. A negative impact of R1/Y10 G>A/C>T changes (RE 6) and of the TA as W5W6 
motif (RE 2) was not apparent, with the exception of the shorter Nutlin treatment. 
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Name of RE RE sequence 
RE1 AGGCATGCCT 
RE3 
GGGCATGCCC 
RE7 (TTTCATGAAA)2                    
RE8 
(GGGCATGCCC)2                   
RE2 
(GGGCTAGCCC)2                
RE6 
(AGGCATGCCT)2 
RE5 
(GGGCAAGCCC)2  
RE9 
(GGGCTTGCCC)2 
RE4 
(AAACATGCCC)2 
Table 2: List of p53 REs (full and half sites) tested in A549 and H1299 cell lines. 
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Figure 7: Luciferase activity of p53 full and half sites cloned in yeast yLFM strain. A total of 20 
(12 full sites and 8 half sites) p53 RE yeast strains, marked along the y-axis, are tested. Luciferase 
activity of WT p53 transformed yeast strains is measured sixteen hours post culturing in synthetic 
selective media in three different galactose concentrations 0.004% (B), 0.008% (C) and 0.032%(D) 
Raffinose culture (A) without galactose is maintained to determine basal p53 protein activity. 
Response Elements exhibiting CWWG core permutations viz. RE5 v/s RE9 and RE2 v/s RE8 are 
compared for statistically significant transactivation differences. * p-value <0.05 for the compared 
adjacent bars (Student’s t-test). # Statistically Non-significant differences  
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 Figure 8: Transactivation potential of p53 full and half sites in H1299 cells expressing variable 
amounts of p53. p53-null H1299 cells are co-transfected with the list of selected p53 REs (see Table 
2), including pGL4.26 empty vector with no RE cloned, and 25ng or 50ng of p53 expressing vector.  
Empty plasmid backbone without p53 cDNA is also transfected along with all RE constructs in H1299 
as a control. Firefly Luciferase activity is measured 36 hours post transfection and the activity of p53 
empty plasmid is subtracted from p53-dependent activity of each RE construct type. Response 
Elements exhibiting CWWG core permutations viz. RE5 v/s RE9 and RE2 v/s RE8 are compared for 
statistically significant transactivation differences. * p-value <0.05 for the compared adjacent bars 
(Student’s t-test). # Statistically Non-significant differences 
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Figure 9: Transactivation potential of selected p53 full and half sites in p53 induced A549 cells. 
A549 cells transfected with selected p53 REs (see table 2) are measured for Luciferase activity upon 
treatment with p53 activating drugs doxorubicin (1.5µM and 3µM) and Nutlin3A (3µM) for 16, 12 and 
8 hours (A, B, C), respectively. The RE constructs transfected but untreated cells are also measured for 
activity at all-time points. Response Elements exhibiting CWWG core permutations viz. RE5 v/s RE9 
and RE2 v/s RE8 are compared for statistically significant transactivation differences. * p-value <0.05 
for the compared adjacent bars (Student’s t-test). # Statistically Non-significant differences  
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2 “outside-the-RE” sequence code for transactivation capacity 
2.1 Impact of sequence flanking the p53 RE on transactivation 
Studies suggest that p53 binding to its RE is regulated by spacer length separating two p53 
binding half sites as well as structural properties such as torsional flexibility of the DNA 
sequence. For example a 10 or 20 bp long spacer element binds more effectively with p53, 
compared with intermediate spacer lengths (143). Other than influencing p53 binding, the 
impact that flexibility and rigidity of the DNA sequence constituting an RE site can have on 
p53-mediated transcriptional strength is a relatively unexplored and intriguing question. 
Generally, a stretch of thymines is considered structurally rigid while guanines impart 
flexibility to DNA. We hypothesised that structural organization of an RE and its contiguous 
flanks characterized by stretch of nucleotides with different rigidity or flexibility can influence 
p53 tetramer assembly and in turn affect the transcriptional output (see Figure 11). As a first 
approach, we exploited different structural organizations of a p53 full site RE derived from 
the p21 promoter, namely the well-established p21-5’ RE that is located ~2.2kb upstream of 
the transcriptional start site (TSS) and that is involved also in the regulation of transcription of 
the long noncoding RNA PANDA from the opposite DNA strand (144).Yeast reporter strains 
incorporating the p53 RE and flanking sequences (6-10nt long) were constructed using the 
previously described method. The two p21-5’ RE decamers (half sites) were annotated as Left 
(L) and Right (R) decamers with respect to the CDKN1A/p21 TSS. These two half sites differ 
in predicted torsional flexibility as the Right half site scores higher in terms of average 
flexibility in comparison to the Left half site (Table 3). Average flexibility of each type of p21 
flank and the RE (half or full site) is calculated manually by adding up the flexibility score 
awarded to each dinucleotide pair (145). The natural LR conformation of the p21 RE was also 
swapped to RL organisation to evaluate the effect on transcriptional strength (22). Also, two 
tandem copies of the Left (LL) or Right (RR) decamers of p21 were tested. The predicted 
affinity (Kd) of all p21 RE permutations explored are presented in Table 3.1. The Kd values 
are calculated using a p53 binding predictor (http://bioinformatics.ibp.cz:8080/#/en/p53-
predictor). All the REs are embedded in the same chromosomal sequence context. To study 
the impact of flanking sequence, yeast reporter strains were constructed where the LR or RL 
REs were flanked by different nucleotide stretches. To reduce experimental variations due to 
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slight changes in RE position relative to TSS, the flanking sequence changes were introduced 
only 5’ to the RE, except for a strain in which a palindromic nucleotide motif was included on 
both sides, to obtain a reporter in which the p53 RE is flanked by sequences predicted to 
possess very similar torsional flexibility. Specifically, we evaluated 10 nucleotides of the 
natural human upstream sequence to p21 LR RE along with other 10-nucleotide flanks 
designed to be either more flexible or more rigid in the context of both LR and RL 
conformation of the p21 RE. See Table 3 for the complete list of p21 RE variants tested.  
 The panel of reporter strains was transformed with empty or p53 expression vectors 
and purified clones were tested under variable galactose amounts to induce p53 at different 
levels and the activity of the reporter was measured at different time points. In these 
experiments, low levels of p53 were considered more relevant under the assumption that at 
limiting protein levels p53 will bind a cognate site as individual dimers and tetramers will 
form at the DNA site. According to a recent study, structural differences of DNA RE sites 
were proposed to contribute to low off rates and were shown to correlate with transactivation 
potential only at low p53 levels (146). 
 The results obtained clearly suggest that LR natural conformation (comprising of 
natural genomic flank) is the most responsive RE of the panel (Figure 10). This is visible at 
basal p53 expression (raffinose T0 and T6) and also at low induction levels (0.002% 
galactose). All the other variants of the 5’ flanking sequence do not significantly differ among 
each other and are lower in activity than the natural flank at T0. Considering instead the p21 
RL RE, the rigid flank shows highest activity which is nearly the double of the LR RE activity 
with rigid flank, followed by neutral, flexible and palindrome in descending order. The trend 
is maintained at T6 in raffinose medium and also at low induction levels (0.002% galactose). 
At higher galactose levels, differences level off; except for the construct containing the 
flexible 5’ flanking sequence that remains the weakest. Maintaining constant the flanking 
sequence (neutral: AATAATACAT) the different version of the p21-5’ p53 RE shows 
differences in transactivation potential. The symmetric LL RE is the most responsive of the 
series at low p53 protein levels, followed by RL, LR and with RR being the least responsive 
in all conditions tested.   
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The predicted log Kd values in Table 3.1 are somewhat consistent to the transactivation 
potentials exhibited by p21 full sites. The least active symmetric RR full site also scores the 
lowest Kd value amongst the other sequences. On the other hand, the average flexibility score 
obtained by the sequences exhibit roughly an inverse correlation with their relative 
transactivation potential (see Table 3). Furthermore, for both p21LR and p21RL REs, we 
establish for the first time that the flanking sequence can impact on transactivation with the 
presence of a rigid flank leading to higher responsiveness compared to a flexible flank. These 
features are apparent at low p53 levels and could be relevant for the regulation of p53 targets 
in unstressed cells. 
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Table 3: Flexibility of p21half or full sites and flanking sequences  
 
Table 3.1: Predicted log Kd values for p21 full sites  
  
Name Sequence Average Flexibility score 
p21 LR (L) HS GAACATGTCC   1.944444 
p21 LR (R) HS CAACATGTTG 2.544444 
RIGID FLANK TAACTTTTCTT 1.34 
FLEX FLANK GAGTAGTATAC 2.55 
PALINDROMIC FLANK  CATATG or GTATAC  3.2  
NATURAL FLANK GGCCGTCAG 2.1 
LL GAACATGTCCGAACATGTCC 1.963158 
RR CAACATGTTGCAACATGTTG 2.505263 
Name Sequence Predicted log Kd 
P21 LR  GAACATGTCCCAACATGTTG -7.11   
P21 RL CAACATGTTGGAACATGTCC -7.04 
P21 LL GAACATGTCCGAACATGTCC -7.38 
P21 RR CAACATGTTGCAACATGTTG -6.77 
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Table 4: List of p21 REs cloned in yeast yLFM via (Delitto Perfetto) 
 
 
Name of p21 RE          Nucleotide Sequence 
  
 
 
   
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
   
Natural Genomic flank 
 LEFT (L) RIGHT (R) 
 flank  flank 
 flank  flank 
Rigid  flank 
 Rigid flank 
 Flexible flank 
 Flexible flank 
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Figure 10: Transactivation potential of p21 RE 
structural variants in yeast. Natural LR and swapped RL 
conformations of p21 RE with genomic (natural) or 
synthetic rigid, flexible and palindromic flanks was tested 
for Firefly luciferase activity in yeast yLFM strain.Three 
concentrations (0.002%, 0.004% and 0.008%) of galactose 
are used for the induction of p53 protein expression in yeast. 
A raffinose (no galactose) culture for all strains is 
maintained in parallel as control. (A) Firefly luciferase is 
measured at time zero for eleven yeast strains cultured in raffinose. The strains are subtracted for 
corresponding empty vector activity to plot the graphs. (B) Firefly Luciferase activity measurements at 
six hours in Raffinose and 0.002% of galactose concentration (C) Luciferase activity in 0.004% and 
0.008% galactose concentration at six hours post induction. Differences between transactivation 
potentials of Rigid and Flex (flexible) flanks are statistically analysed as shown * p<0.05, student’s t 
test. # statistically non-significant 
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2.2 Impact of sequence flanking the p53 RE on relative transactivation 
strength of a bidirectional promoter. 
These experiments were performed in collaboration with prof. Tali Haran (Technion, Haifa, 
Israel) who spent a sabbatical period in Trento in 2015. 
We implemented another strategy to study the impact of structural properties of the p21 RE and 
flanking sequences that can also evaluate bidirectional transcription. Both the p21 LR and RL 
conformations were tested with natural flanks on both sides or with designed flanks that 
maximize the differences in torsional flexibility at the two sides of the RE. Those Extra-Flex or 
Extra-Rigid sequences were chosen examining the natural flanking sites of well-established p53 
REs. Hence, the LR-EFR construct contains the p21 LR RE with the extra flexible motif 
upstream of the L half site and the extra rigid one downstream of the R half site (see Figure 13). 
On the other hand the RL-EFR construct carries the extra flexible flank upstream of the R half 
site and a rigid flank downstream to L half site. These constructs were cloned as annealed double 
strand oligonucleotides at the centre of a bidirectional GAL1,10 promoter, transcribing Firefly 
and Renilla luciferases from GAL1 and GAL10, respectively (see Materials and Methods) (also 
see Figure 14).  The ligation exploited a single Age I restriction site, and clones that incorporated 
the annealed oligos in both orientation were obtained and characterized, see Table 5 for the list 
of oligos. For example, for the p21-LR with natural flank construct we obtained two reporters 
that were labelled p21-LR_LUC, for the case of the forward oligo (5’-3’) becoming part of the 
same strand of GAL1-Firefly cDNA and p21-LR_REN, for the case of the forward oligo 
becoming part of the same strand of GAL10-Renilla cDNA. Given the bidirectional nature of the 
GAL1,10 plasmid, the p21-LR_LUC construct contains a p21 RL-reverse strand- acting as 
enhancer of Renilla transcription (see Figure 12). The same arrangement occurs for the construct 
containing synthetic flanks, such that when the forward LR_EFR oligo becomes part of the 
Firefly Luciferase cDNA strand in 5’-3’ orientation, the resulting construct is labelled 
LR_EFR_LUC. For the Renilla reporter then the enhancer will be in conformation extra-
Rigid_RL_extra-Flex (see Figure 13). Conversely, when the Reverse LR_EFR oligo (5’-3’) 
becomes part of the same strand of the GAL1-Firefly cDNA, the construct is labelled 
LR_EFR_REN as the p21 extra-Flex_LR_Extra-rigid is the enhancer for GAL10-Renilla (see 
Figure 13). All these constructs were developed within the centromeric pRS 314 plasmids 
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(TRP1) and transformed in the yIG397 yeast strain along with p53 expressing plasmid (LEU2) or 
empty pRS315 vector as control (see Materials and Methods, and also see Table 5 for the list of 
p21 oligonucleotides that were cloned). The goal of the experiment was to check if the 
configuration of the p53 RE and flanking sequence can impact on transactivation strength and/or 
directionality. As for the previous experiments, variable level of p53 expression was obtained 
culturing cells in media containing different galactose concentrations and for different time 
points. An empty dual-luciferase GAL1,10 reporter plasmid was included as a control to measure 
the Firefly and Renilla Luciferase activities independent from p53 function as transcription factor 
at the site.  
We observed that p21 REs appended with Synthetic EFR flanks (extra flex/rigid) were much 
more active than those containing natural genomic flanks (activity of LR/RL EFR > LR natural). 
The RL_EFR_LUC (flexible flank upstream to Right half site and rigid flank downstream to Left 
half site close to GAL1 TSS) was the most responsive strain in terms of both Firefly and Renilla 
luciferases activity whereas RL_EFR_REN (flexible flank downstream to R half site on the 
GAL10 strand) was the least active. These differences were observed at basal p53 expression 
(Raffinose) and also at 0.004% and 0.008% galactose concentration after six hours of induction 
(Figure 15). This informs that for p53-mediated transcription, a torsionally rigid flank is 
preferred next to the TSS and presence of a flexible flank immediately adjacent to TSS can 
reduce transactivation. We also calculated the average flexibility score for the p53 REs and 
flanks appended upstream as well as downstream to the p21 REs (see Table 6). Considering the 
RE half site (HS) as functional units recruiting p53 dimers, the overall organization 
Flexible(flank)-Rigid(HS)-Flexible(HS)-Rigid(flank)-TSS results in the highest transcription 
induction.  
One inference drawn from these observations was possibility of promoter biasness as the GAL1 
promoter was transcriptionally more active than GAL10 in our experimental setting. We then 
reversed the promoter orientation so to place the Firefly cDNA under GAL10 promoter and 
Renilla cDNA under GAL1 promoter (see Materials and Methods), for the control plasmid and 
the p21 series (natural flanks or EFRs: LR_LUC, LR_REN, LR_EFR_LUC, LR_EFR_REN, 
RL_EFR_LUC, RL_EFR_REN) 
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Testing those new constructs in yIG397 led to overall higher Renilla Luciferase activity, as 
expected. We confirmed that the Flexible(flank)-Rigid(HS)-Flexible(HS)-Rigid(flank)-TSS 
results in the higher transactivation (Figure 16). Furthermore, with the GAL10-Firefly GAL1-
Renilla configuration, the impact of this structural feature was simultaneously observed on both 
directions of transcription. In other words with the RL_EFR_LUC orientation there was a 
relative gain in Firefly vs Renilla activity whereas the opposite was true for the RL_EFR_REN 
orientation (Figure 16). Again, these differences were significant only at low p53 expression 
level. 
 
 
 
Figure 11: p53 RE in genomic context. A p53 RE is flanked by a stretch of contiguous nucleotides in 
genome. The interactions between p53 tetramer or dimer and a p53 RE, shown as a full canonical RE in 
this case, can also be influenced by surrounding nucleotide flanks depending on their physical properties 
and identity with respect to the genomic context. 
 
 
 
 
 
Figure 12: Cloning schematics of p21 LR_LUC construct:  Sixty six nucleotides long p21 LR Forward 
and complementary Reverse oligo face Firefly LUC and Renilla LUC in 5’-3’ orientation, respectively.  
The p21 full site contains two palindromic decamers Left (L, in red) and Right (R, in blue). The full site is 
immediately followed by genomic flanks contiguous to p21 RE in chromatin environment (in italics). 
Both forward and reverse strands carry AgeI restriction overhangs used for cloning in suitable vector 
(RGF pRS 314). The figure describes orientation 1 of cloning. 
RIGHT (R) LEFT (L) 
RRRCWWGYYYRRRCWWGYYY NNNNNNNNNNN NNNNNNNNNNNN
N 
p53 
p53 
p53 
p53 
Contiguous flanks 
P53 binding full site 
? ? 
Contiguous flanks 
                             5’-CcggtattggctttctggccgtcagGAACATGTCCCAACATGTTGagctctggcatagaagaggca-3’ 
             
                                        3’ ataaccgaaagaccggcagtcCTTGTACAGGGTTGTACAACtcgagaccgtatcttctccgtggcc 5’ 
                                                                 
   
 
 
 
 
 
 
  
P21LR-age_FW facing firefly LUC: (orientation 1) 
 Genomic flank Genomic flank 
FIREFLY LUC 
REN LUC 
P21LR-age Rv facing Renilla LUC 
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LR_EFR_LUC  
p21 LR-EFR-AgeI_Fw oligo _ facing Firefly luciferase : (orientation 1) 
 
     5’  ccggtagcagcacacacacacacacGAACATGTCCCAACATGTTGgctaatttttgtaatttttta-3’ 
 
 
 
 LR_EFR_REN 
p21 LR- EFR age_Rv: Facing firefly luciferase: (orientation 2) 
   
 
     5 ccggtaaaaaattacaaaaattagcCAACATGTTGGGACATGTTCgtgtgtgtgtgtgtgctgcta-3’ 
        
 
Figure 13: Cloning schematics of LR_EFR_ LUC and LR_EFR_ REN. Sixty six nucleotides long p21 
LR EFR forward and reverse oligos are annealed and phosphorylated. In LR_EFR_LUC orientation 1, the 
Left (L) decamer faces a synthetic torsionally flexible flank next to Transcriptional start site of Firefly 
Luciferase cDNA, whereas the Right (R) decamer faces a synthetic rigid flank. Age1 restriction over 
hangs is used for cloning in suitable vector (RGF pRS 314). In LR_EFR_REN orientation 2, the rigid 
synthetic flank is next to the Right half site and flexible synthetic flank adjacent to Left half site faces 
transcription start site of Firefly Luciferase cDNA. 
 
 
 
 
 
 
LEFT (L) 
        AgeI site Synthetic flexible flank Synthetic rigid flank 
RIGHT (R) 
Synthetic flexible flank 
RIGHT (R) LEFT (L) 
FIREFLY LUC 
FIREFLY LUC 
      AgeI site Synthetic rigid flank 
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Figure 14: Bidirectional plasmid (RGF pRS 314) transcribing Firefly and Renilla Luciferases from 
Galactose inducible GAL1 and GAL10 promoters, respectively. Sixty six nucleotides long 
phosphorylated double strand DNA oligonucleotide carrying p53 RE is ligated with Age I digested RGF 
pRS 314 plasmid promoter. The DNA oligos are ligated in both forward and reverse orientation facing 
Renilla and Firefly Luciferase, respectively.  
  
P53 RE G10 G1 
RENILLA LUCIFERASE cDNA 
Forward/Reverse oligo  
Two orientation cloning 
Forward/Reverse  oligo  
5’ RRRCWWGYYYRRRCWWGYYY 3’ 
RENILLA 
LUC 
FIREFLY 
LUC 
FIREFLY LUCIFERASE cDNA 
RGF pRS 314 
w TRP1 selection 
marker 
3’ RRRCWWGYYYRRRCWWGYYY 5’ 
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Table 5: List of p21 RE variants with flanks cloned in bidirectional RGF plasmid 
  
Name of 
oligonucleotide 
Sequence 
P21LR-age_FW 5’ ccggtattggctttctggccgtcagGAACATGTCCCAACATGTTGagctctggcatagaagaggca 3’ 
AgeI site   Genomic flank           LEFT(L)         RIGHT(R)            Genomic flank             
                                                       P21 canonical Full site 
P21LR-age_Rv 5’ ccggtgcctcttctatgccagagctCAACATGTTGGGACATGTTCctgacggccagaaagccaata 3’ 
AgeI site  Genomic flank          RIGHT(R)           LEFT(L)              Genomic flank             
                                                       P21 canonical Full site 
p21LR-EFR- age_Fw 5’ ccggtagcagcacacacacacacacGAACATGTCCCAACATGTTGgctaatttttgtaatttttta 3’ 
AgeI site Synthetic flexible flank  LEFT(L)         RIGHT(R)        Synthetic Rigid flank             
                                                     P21 canonical Full site 
p21 LR-EFR-age_Rv 5’ccggtaaaaaattacaaaaattagcCAACATGTTGGGACATGTTCgtgtgtgtgtgtgtgctgcta 3’ 
AgeI site  Synthetic rigid flank    RIGHT(R)       LEFT(L)           Synthetic flexible flank             
                                                     P21 canonical Full site 
p215RL-EFR-age_Fw 5’ccggtagcagcacacacacacacacCAACATGTTGGAACATGTCCgctaatttttgtaatttttta 3’ 
AgeI site Synthetic flexible flank  RIGHT(R)    LEFT(L)          Synthetic Rigid flank             
                                                     P21 canonical Full site 
p215RL-EFR-age_Rv 5’ccggtaaaaaattacaaaaattagcGGACATGTTCCAACATGTTGgtgtgtgtgtgtgtgctgcta 3’ 
AgeI site  Synthetic rigid flank      LEFT(L)        RIGHT(R)   Synthetic flexible flank             
                                                     P21 canonical Full site 
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Table 6: Calculation of flexibility score for the nucleotides forming p21 RE flank 
 
 
Position, Features and name of flanking 
sequence  
Sequence (20 nts)  Flexibility score 
Upstream genomic flank to a p21 LR Fwd attggctttctggccgtcag  1.931579 
 
Downstream genomic flank to p21LR Fwd 
 
agctctggcatagaagaggc  
 
1.947368 
 
Extra flexible flank upstream to p21 EFR LR 
 
agcagcacacacacacacac  
 
2.689474 
 
Extra rigid flank downstream to p21 EFR LR gctaatttttgtaatttttt  
 
1.521053 
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Figure 15: Dual luciferase activity of p53 RE integrated in Bidirectional plasmids in yeast. The yeast 
cells are transformed with RGF pRS 314 constructs LR_LUC, LR_REN, LR_EFR_LUC, LR_EFR_REN, 
RL_EFR_LUC and RL_EFR_REN, respectively, along with WT p53 expression plasmid or empty vector 
pRS 315. The transformed strains are cultured in selective synthetic media in 96 well plates with two 
concentrations of galactose (0.004% and 0.008%).  A parallel raffinose culture (no galactose) is used as a 
control for all the strains. The dual Luciferase activity of empty vector transformed strains is subtracted 
from the p53 expressing strains to plot the values as shown above. (A) Dual luciferase activity exhibited 
by bidirectional constructs at time zero in Raffinose media. R Luc signifies Renilla Luciferase readings 
and F Luc signifies Firefly luciferase. Dual Luciferase is also measured at six hours post culturing the 
yeast cells in Raffinose media (B), 0.004% galactose (C), and 0.008% galactose (D). * p<0.05 for the 
compared bars, Student’s t-test . # Statistically non-significant differences  
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Figure 16: Dual Luciferase activity of reversed galactose inducible bidirectional promoters. Dual 
luciferase activity of the constructs with reversed promoters is measured at 0.004% (C) and 0.008% 
(D) galactose concentration six hours post culturing in selective media as described previously. Also, 
all the cultures are maintained in selective raffinose media (no galactose) and measured for their 
activity at time zero (A) and six hours post culturing (B). The F luc is Firefly activity from GAL10 
promoter and R luc signifies Renilla transcription from GAL1 promoter. * p<0.05 for the adjacent 
compared bars ( student’s t test), # Statistically non-significant differences. 
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Part B. NF-кB studies 
1. Quantitative analysis of transactivation potential and specificity of NF-кB proteins in 
yeast and human cell lines  
These experiments have been presented in a paper published last year, that is appended here, 
of which I am the first author. The text below summarizes the state of the art, rationale and 
results of the publication.  
Similar to p53, NF-кB proteins recognize a binding site (кB-RE) with a rather loose 
consensus sequence. While p53 is active as a tetramer, NF-кB acts as a dimer, and both 
homodimers and heterodimers can be formed between the various family members. 
Depending on the cell type, the predominant active NF-кB form may differ (see also Table 1, 
page 30). Various non-traditional dimer-specific NF-кB binding sites are identified through 
protein binding microarrays and surface Plasmon resonance techniques without any 
knowledge of their transactivation abilities (128, 147). Hundreds of NF-кB binding sites 
(canonical as well non canonical) are identified and characterized through EMSA, ChIP-seq, 
or Selex studies (128, 148-150). Results established a wide range of DNA binding affinities 
and identified that even single nucleotide changes can impact both on affinity and selectivity 
of NF-кB protein interactions (125). In my thesis work, I completed the development of a 
yeast-based functional assay to examine transactivation potential and specificity of NF-кB 
proteins, namely p65 and p50, towards a panel of binding sites. In total, we constructed 17 
reporter strains using the methodology of oligonucleotide targeting described in the Methods 
section and also in the paper included here. The кB-RE panel included examples of NF-кB in 
vivo targets, present in the MCP-1, IP-10, and IFNβ promoters and others chosen to sample 
single nucleotide variations in the binding sites resulting in differences in binding affinity 
(125). We also compared reporters with a single кB-RE (10mer), and two repeats, either 
adjacent or spaced.  
 Inducible expression vectors were constructed for p65/relA and p50. Given that p50 
does not possess a transactivation domain, we also constructed a chimeric p50 (p50 fused with 
a p65 TAD) that enabled us to study relative transactivation potential of p50 homodimers.  
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The results presented in the paper indicate that p65 and p50TAD chimera (p50 fused with a 
p65 TAD) exhibited distinct transactivation specificities. The co-expression of p65 and 
p50TAD led to a change in transactivation specificity. We also tried to test in the assay the 
impact of trans regulatory factors (small molecules or protein cofactors). We cloned the IкBα 
cDNA under a constitutive promoter on a plasmid that is leucine auxotrophy selectable and 
co-transformed it in the most p65-responsive yeast strain. We observed 50% down regulation 
in p65 activity in terms of luciferase activity, consistent with a previous study (151), but with 
the advantage in our settings of inducible expression of p65. Two small molecules, Ethyl 
Pyruvate and BAY 11-7082, showed a dose dependent impact on NF-кB transactivation, 
suggesting a potential use of the assay to screen for small molecules targeting the activity of 
specific NF-кB proteins. 
Overall, this study confirms that NF-кB proteins exhibit intrinsic nucleotide preferences as 
sequence-specific transcription factors and the formation of heterodimers p65/p50 provides 
for a change in transactivation specificity and that, in principle, small molecules can be 
identified in a yeast system which alter transactivation specificity. Considering the sequence 
features of кB-REs, we confirmed that a change of single nucleotide can increase or decrease 
transactivation potential of a RE drastically. Although, we noticed an overall low correlation 
between relative DNA binding affinities measured in vitro and transactivation potential with 
the yeast-based assays. Finally, considering the contiguous arrangements of multiple кB-REs, 
we observed additive or nearly additive interactions, contrary to the case with p53, where 
cooperative interactions are influenced by the spacer between full site REs (77).  
 
To check if the yeast based NF-кB transactivation profiles hold significance in mammalian 
cells as well, we tested 4 кB-REs. Each of these REs was more active with a different NF-кB 
dimer in yeast. The REs were cloned in pGL4.26, upstream of a Firefly luciferase cDNA, and 
transfected in breast cancer cell line MCF-7, a cell line that can activate the canonical NF-кB 
pathway in response to TNFα treatment. Hence, rather than using ectopic expression of 
different NF-кB proteins, I treated transfected MCF7 cells with different doses of NF-кB 
inducing chemokine TNFα for 4 -8 hours, respectively. I observed that also in MCF7 cells, the 
order of transactivation potential exhibited by the кB-REs matches the results in yeast, 
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suggesting that the reported assay in the lower eukaryotes can be predictive in assessing 
relative transactivation of кB-REs. For example, the M2 RE identified as one of the most 
potent in yeast, is highly active in MCF7 cells. Treatment of transfected cells with NF-кB 
inhibitor BAY 11-7082 reduced the RE-mediated transactivation in terms of Firefly luciferase 
activity confirming that the observed activity is mainly NF-кB dependent.  
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DISCUSSION 
Exploiting single nucleotide variants of p53 and NF-кB REs in yeast as well as human cell 
lines we established that each nucleotide individually or in cooperation with the adjacent 
nucleotides contributes to p53 and NF-кB transactivation specificity. We studied a list of p53 
(20 REs) and NF-кB REs (17 REs) in yeast as well as human cell lines. Ad-hoc variation of 
p53 REs, which were used to probe allosteric changes in p53 DNA binding domain and target 
DNA conformation by crystallization studies (H. Viadiu, unpublished), were evaluated for 
their transactivation potential, providing insights on the individual contribution of nucleotides 
on the transcription function of an RE. p53 and NF-кB REs studied in yeast chromatin context 
illustrate a DNA nucleotide code that was at least in part predictive of their function in human 
cell lines. The correlation was less apparent between transactivation data and measured or 
predicted DNA binding affinity with naked DNA. 
Certain REs are active at low p53 levels whereas others show activity at moderate p53 
concentration in cells confirming the correlation between p53 recognition and relative 
transactivation. This study also confirms that stretch of three guanines (GGG) in the 5’ end of 
RE is structurally flexible and potentiates p53-mediated transactivation. Also, a CATG core 
within the RE facilitates transcription much more than CTAG, CTTG or CAAG. Surprisingly, 
the high transactivation potential exhibited by (AAACATGCCC)2
 
reveals a positive impact of 
a stretch of adenines in the 5’ end of the decameric RE motif. On the contrary, but as 
expected, the presence of thymines in the 5’ ends of RE adversely affects the strength of an 
RE in terms of transactivation. Overall, a torsionally flexible 5’ end of RE leads to higher 
transactivation whereas a rigid 5’ end of the RE is detrimental for transcription. 
Using structural variants of the p21-5’ RE also established that physical properties of a RE 
can modulate transcription. Constructing an artificial p21 RE by swapping the half sites from 
LR to RL conformation reveals that the natural p21LR conformation is more potent and 
replacing the genomic flank appended upstream to the p21 RE with an artificial flank reduces 
the overall transactivation potential of the RE. On the contrary, quantification of 
transactivation potential of p53 REs in bidirectional plasmid environment reveals that a p21 
RE is more potent when appended with synthetic flexible and rigid nucleotide flanks. Natural 
genomic flanks of the p21 RE present on both sides of the RE are somehow less active in this 
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case. Also, the dual Luciferase assays reveal artificial p21 RL conformation slightly more 
active than the LR conformation in galactose-induced yeast cultures suggesting that DNA 
sequence dependent structural specificity within RE code controls transactivation. Also, it 
suggests that in addition to nucleotides upstream to a RE, the nucleotides close to a 
transcription start site (TSS) also affect transactivation differentially. This was confirmed with 
the bidirectional Firefly and Renilla Luciferase assay performed in both orientations for each 
p53 RE where a rigid flank next to TSS leads to higher transactivation. Also, arrangement of 
nucleotides within and outside an RE can control direction of transcription as observed in 
some cases such as RL_EFR_LUC/REN (see Figure 15).  
Overall the study confirms that torsional rigidity or flexibility of nucleotides forming a p53 
RE in context with contiguous nucleotides (DNA flanks) alters the transactivation potential of 
an RE. Also, contiguous genomic flanks to a p53 RE impart structural variability to DNA and 
partially control strength and direction of transcription. 
Further studies are needed to determine how genomic flanks upstream and downstream to a 
p53 RE can affect the transcriptional decisions to reach definite conclusions. A rigorous 
analysis of flanks contiguous to other p53 REs in the genomic background has to be assessed. 
Also, variations in the length and nucleotides can be incorporated in the genomic flanks 
studied in bidirectional promoter system. Another speculation is the correlation between 
flexibility scores (see Table 3) of a DNA sequence (upstream flank-LHS-RHS-downstream 
flank) and relative transactivation potential with respect to p53 concentrations in the vicinity. 
A generic view describes that alternate flexibility scores (high low high low or low high low 
high) obtained by half sites and flanks comprising a DNA sequence favour low p53 
concentrations to initiate transcription (Raffinose cultured yeast cells). It is also known that 
p53 as a dimer recognises half site decamers to control transcription. On the contrary, a linear 
descending flexibility score (high to low) shows maximum transactivation with high p53 
levels (yeast cells cultures in the presence of galactose) hinting p53 tetramers as functional 
TFs in this case. The link between flexibility patterns of a sequence and relative 
transactivation was addressed previously by Olson et al. As a future direction, we aim to 
establish more precisely the correlation between flexibility patterns exhibited by a DNA 
sequence and the relative transactivation potentials.  
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                                Research Project 2 
2. p53 and NF-кB: partners in crime 
The experiments described here are a follow-up of a published study in which I am a co-
author. The paper is presented in the Appendix. Here I summarize unpublished work I 
developed to further investigate the impact of combined treatment with doxorubicin and 
TNFα on cell migration and mechanisms of p53 and NF-кB transcriptional cooperation  
Typically, p53 and NF-кB have antagonistic functions in different cell types and extrinsic and 
intrinsic stress responses activate p53 and NF-кB, respectively, to reciprocally regulate each 
other at cardinal intersections of various pathways (152). Various reports identified or 
proposed examples of cooperative interactions between the two families of proteins leading to 
differential regulation of genes involved in cancer. p53 and NF-кB can act as co regulators of 
proinflammatory responses driving the expression of IL-6 and CXC1 in macrophages and this 
was revealed also after nongenotoxic p53 activation by Nutlin-3A treatment (153). Mutant 
p53 is also reported to enhance the activity of NF-кB induced by TNFα in different cancer 
types affecting tumor aggressiveness and responses to therapy (154, 155). According to other 
reports, the chemotherapeutic agent doxorubicin enhances NF-кB’s transcriptional activity in 
a p53 deficient environment whereas the treatment of lung cancer cells with Nutlin-3A down-
regulates TNFα-induced NF-кB pathway in a p53-dependent manner (156, 157). It has also 
been proposed that p53 and NF-кB proteins have diverged out from a common ancestral TF 
involved in cell regulation and apoptosis. Both p53 and NF-кB interact with ankyrin proteins 
and recognize a similar DNA sequence as their binding sites share an 80% similarity (158).   
In a recent study I contributed to (see Figure 6 and supplementary Figure S3 in Appendix), 
transcriptome changes were analysed in MCF7 cells treated by doxorubicin or TNFα as single 
agents or by the combination of the two. The combined treatment leads to a synergistic up 
regulation of many genes, some previously reported to be involved in cancer and metastasis. 
Promoter analysis, including ChIP assays, suggested a possible direct interplay between p53 
and NF-кB proteins at the transcriptional level. Also, qPCRs performed on some selected up-
regulated genes (PLK3, LAMP3, ETV7, NTN1, UNC5B) established that doxorubicin and 
TNFα mediated activation in MCF7 cells require p53, as revealed by the used of an MCF7-
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shp53 derivative line (159). More recently, another report proposes interplay between p53 and 
NF-кB downstream of TLR5 activation, leading to synergistic expression of more than 200 
genes. Treatment of cells with TNFα, an activator of NF-кB, increases cytokines’ expression, 
such as IL6 and CXCL2, in a p53-dependent manner (160). This encouraged us to study p53 
and NF-кB interplay using doxorubicin and TNFα as p53 and NF-кB activators, respectively. 
I developed experiments to examine the regulation of identified, synergistic signature genes in 
additional cell lines (2.2.1) and evaluated the impact of the treatments on the migration 
potential of those cells (2.2.2) –see also supplementary data of the publication in Appendix-. 
Next, I have explored the potential role of trans-factors, namely TIP60 and MOF histone 
acetylases in the crosstalk between p53 and NF-кB (2.2.3). Finally, to study more directly the 
control of selected gene promoters by p53 and NF-кB, I constructed reporter assays and 
examined if the transcriptional cooperation could be confirmed and linked to specific cis-
elements (2.2.4).  
 
Molecular mechanisms contributing to doxorubicin and TNFα synergy 
Various intricate molecular mechanisms could underlie the transcriptional synergy upon 
doxorubicin and TNFα combined treatment, besides the stabilization and nuclear localization 
of p53 and NF-кB proteins. These can include a potentially high number of cofactors and 
molecules that can alter the transcriptome and modify the chromatin landscape (161-163). 
Given the genetic or pharmacological evidences of an involvement of both p53 and NF-кB, 
we decided to investigate a few specific transcription cofactors like histone acetyl transferases 
(HATs), and histone deacetylases (HDACs) (69, 111, 164, 165). In particular, I began 
investigating the impact of TIP60 and MOF, two MYST family histone acetyl transferases in 
regulating doxorubicin+TNFα-mediated transcriptional synergy.  
TIP60 (HIV Tat-interacting protein, 60 kDa) was identified as a transactivation enhancer of tat 
protein at HIV-1 promoter. It acetylates lysine residues in the amino terminal tail peptides of 
histones H2A, H3 and H4, but not H2B (166). Overall, TIP60 is a cell-type specific 
transcription co-regulator acting on wide variety of transcription factors such as the androgen 
receptor, MYC, STAT3, NF-кB, E2F1 and p53. Also it is involved in various cellular 
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processes such as cellular signalling, DNA damage repair, cell cycle and checkpoint control 
and apoptosis (167-169). It is also known as a negative regulator in association with STAT3, 
p73, CREB (cAMP response element-binding protein) and ZEB (zinc finger E box-binding 
protein) (170, 171). TIP60 regulates both p53 and NF-кB transcriptional activity through 
acetylation of lysine 120 and 310, respectively. TIP60-dependent acetylation of p53 controls 
the cell fate between cell cycle arrest and apoptosis (172). Reports suggest that K120 
acetylation of p53 by TIP60 selectively increases p53 binding to apoptotic gene promoters at 
sites that exhibit low affinity (173). TIP60 is also involved in NF-кB pathways through direct 
protein-protein interactions with RelA/p65, but also indirectly, as proposed for the NF-кB 
targets IL6 and IL8 (174, 175).  
MOF is another of the MYST HAT that can acetylate p53 at K120 and direct cells towards an 
apoptotic response. MOF also plays other important roles in gene regulation as the primary 
acetyltransferase for H4K16 acetylation, which initiates chromatin remodelling and 
transcriptional regulation (176, 177) 
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2.1 MATERIAL AND METHODS 
Cell lines, culture conditions & drug treatments 
A549 cells were obtained from ATCC (Manassas,VA, USA) while H1299 cells were a gift of 
Dr. Resnick’s laboratory (NIEHS, NIH, RTP, NC,USA). Cells were cultured in DMEM or 
RPMI media supplemented with 10% FBS and Low Serum Growth Supplements (Life 
Technologies, Milan, Italy). Treatment doses were the following: doxorubicin (Doxo, 1.5 
μM); Nutlin-3A (10 μM); TNF-α (5ng/mL in MCF7; 10ng/mL in H1299 and A549 based on 
response tests with gene reporter assays); BAY 11-7082 (20μM in H1299 and A549). All 
compounds were from Sigma-Aldrich (Milan, Italy). 
 
RNA isolation and quantitative qPCR 
Total RNA was extracted using Qiagen RNeasy Kit (Qiagen, Milan, Italy). cDNA was 
converted from 1 µg of RNA using M-MuLV reverse transcritptase and RevertAid cDNA 
Synthesis kit (ThermoFisher, Milan, Italy). qPCR was performed on a Bio-Rad CFX384 (Bio-
Rad, Milan, Italy). TaqMan gene expression assays (Applied Biosystems, Life Technologies) 
and Probe MasterMix (Kapa Biosystems, Resnova, Rome, Italy) were used starting with 25ng 
of cDNA as previously described [56, 61]. GAPDH, B2M or ACTB served as reference 
genes.  
 
Migration and wound healing assays 
The migration potential of A549 and H1299 cells was monitored by a real-time approach 
using the xCELLigence RTCA Instrument (Acea Biosciences, Euroclone, Milan, Italy) in 
CIM-16 plates, following manufacturer’s instructions. 80% confluent cells were left untreated 
(mock) or treated with Doxorubicin, TNFα or the combination. 16 hours after the treatments, 
cells were detached and added to the top chamber in serum-free medium. Migration was 
detected every 10 minutes for 24 hours. Migration assays were also performed using the 
Transwell migration kit (Millipore). 
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Cloning of promoter/enhancer regions of signature genes and Luciferase reporter 
measurement.  
 
A pair of primers to amplify the promoter/enhancer region of selected genes was designed 
with appropriate restriction site overhangs (see Table 7 for the list of putative REs in the 
promoter/enhancer regions cloned and Figure 17 for a schematic view of the cloned fragments 
and position of the putative REs). The amplified DNA was cloned upstream to Firefly 
Luciferase cDNA in pGL4.26 vector digested with corresponding enzyme pair using the 
cloning protocol. The correct clones were selected with restriction digestion patterns and 
Sanger sequencing. 60% to 70% confluent MCF-7 cells were transfected with 250ng plasmid 
DNA of each clone type and 50ng of Renilla Luciferase expression plasmid (pRLSV40) for 
24 hours using miRUS LT1 transfection agent, followed by Doxorubicin, TNFα, or 
Doxorubicin + TNFα treatments for another 16 hours. The experiment was performed in 
triplicates using 24-well plates and the Firefly and Renilla Luciferase activity was measured 
according to manufacturer’s protocol.  
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Table 7: The table enlists the nucleotide sequence of p53 and NF-кB Response elements embedded in 
promoter or enhancer regions of the signature genes. Using TRANSFAC DNA regulatory element 
pattern search tool, putative p53 and NF- кB REs with a minimum cut off score of 0.9 were selected. 
 
GENE promoter/ 
enhancer 
                p53 (RE)      NF-кB (RE) 
NTN1_PROMOTER+I
NTRON1 
GCCGGGCATGGAGCTG 
AGACCGGCTCAGGCATGCCC 
AAAGTCCC     
CGGACTTTCC   
GGGACTTT   
 
PLK3_PROMOTER GGGCCAGGCAAGCCAGGCGC 
TAACATGCCCGGGCAAAAGCGAGCGC 
TGGGAGTTCC 
GAAATTCCA 
DUSP5_PROMOTER  CAACAAGCCCTTGTCTAGTGCGGG CCTGGGGACC 
ETV7 _ INTRON1 
AGGCAAGTCC 
 
GGAATTCCCC  
 
LAMP3_PROMOTER AGGCATGTGCCACCATGCCC CGGAGTTT  
TGGAATTTCC 
EGR2_INTRON 2 AGACATGTCA AAGGCCCCAGC  
TGGAATTTCC  
EDN2 
INTRON2+EXON2+IN
TRON3 
CTGCAAGCCCGGGCATGCCC 
  
GGGACTTT 
AAAGTCCC 
 
SNAI 1 promoter GGGCATGCCC CCAGGGGAGTTTT 
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Figure 17: Schematics of putative p53 and NF-кB REs distribution in enhancer /promoter 
regions of five signature genes. (a) ETV7 intron 1 carries a 10mer NF-кB RE and a p53 half site with 
mismatches at position one and eight. (b) Intron1 of NTN1 is scored for three NF-кB and two p53 
REs. One of the NF-кB sites is a10mer and the other two are 8mers. The two p53 half sites obtained 
high PWM score inspite of mismatches. (c) LAMP3 promoter has two NF-кB sites (10 mer and 8 mer) 
and a p53 full site. (d) EDN2 intron 3 has an overlapping p53 and NF-кB binding site making a full 
20mer RE. Also, it has two 8 mer NF-кB REs. (e) DUSP5 promoter has a p53 quarter site and a 10 
mer NF-кB site.            P53 RE            NF-кB RE 
INTRON1T ETV7  
intron1 EXON1 
EXON2 
TSS 
5’UTR 
36,387,783 
36,386,995  
1KB 
GGAATTCCCC   
1.45KB 
EXON2 EXON
1 
NTN1 
intron1 
5’UTR 
TSS 
9021542  
GCCGGGCATGGAGCTG 
AAAGTCCC CGGACTTTCC 
AGACCGGCTCAGGCATGCCC 
GGGACTT
T 
EXON1 5’UTR 
183,162,911 
LAMP3 
promoter 183136697  
1.4KB 
CGGAGTTT 
AGGCATGTGCCACCATGC
CC 
TGGAATTTCC 
TSS 
EXON3 EXON4 
1.27KB 
41482465  
CTGCAAGCCCGGGCATGC
CC 
GGGACTTT AAAGTCCC 
EDN2 
intron3 
DUSP5 
promoter 
EXON1 5’UTR 
 
110497838  
CAACAAGCCCTTGTCTAGTGCGGG 
CCTGGGGACC 
1KB 
TSS 
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Ectopic expression assays. 
500ng of TIP60 or MOF expressing plasmids were expressed in 70% to 80% confluent A549, 
MCF7 and H1299 cells in 6-well plates using Lipofectamine or miRUS LT1 transfection 
agents. H1299 cells were transfected with 200ng of p53 expressing plasmid for 10
5
 seeded 
cells. Also, empty vector with pSUPER backbone was transfected as a control in all cell lines. 
24 hours post transfection, cells were treated with doxorubicin, TNFα or Doxorubicin+TNFα 
as described earlier.  
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2.2 RESULTS 
2.2.1 Treatment of A549 cells with Doxorubicin + TNFα synergistically up regulates 
genes involved in metastasis, mitosis and kinetochore formation.  
Previously, a transcriptome analysis of MCF7 cells treated with doxorubicin + TNFα 
identified synergistic upregulation as well as downregulation of numerous genes (defined as 
differentially expressed genes, DEGs). Transcriptome data was confirmed through qPCR for 
12 of 15 selected genes, which were transcriptional targets of either doxorubicin and/or of 
TNFα treatments and synergistically up-regulated upon Doxo+TNFα double treatment. Five 
of these genes (ETV7, PLK3, UNC5B, NTN1 and LAMP3) were of particular interest either 
because of the magnitude of transcriptional changes or due to their functions.  
To extend the analysis of synergistic regulation to other cell lines, I explored the impact of 
doxorubicin and TNFα individually as well as combined on HCT116, A549, and H1299 cell 
lines. Part of this data was published and is presented in Appendix. Here I present additional 
unpublished data. 
A549 and H1299 are Non-Small Lung carcinoma-derived cell lines, of which the first 
expresses wild type p53, while the second is considered a true p53 null. Firstly, I performed 
gene reporter assays to establish the minimal dose of TNFα needed to activate NF-кB 
dependent transcription in these cells (10ng/mL) Also, the effective dose of BAY 11-7082 
(20µM), a known pharmacological inhibitor of NF-кB activity, was identified. 
Next, qPCR was performed using total RNA. A549 cells had exhibited a highly synergistic 
expression of 3 genes ETV7, LAMP3 and NTN1. For other two genes (UNC5B, PLK3), the 
responsiveness upon combined treatment was simply additive (see Figure 6 in paper attached 
in Appendix). Eight additional genes from the initial list of 15 were tested of which EDN2, 
NPCC and EGR2 were responsive to doxorubicin and PLAU was responsive to TNFα and 
enhanced by double treatment (Figure 18).  
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Figure 18: Selective transcriptional synergy of genes in Doxorubicin (D), TNFα (T) and 
Doxorubicin + TNFα (DT) treated A549 cells. qPCR was performed using RNA extracted from 
treated (M (mock), D, T, DT) A549 cells to quantify the expression of EDN2, NPPC, Snai1, EGR2, 
PLAU, SOX9 and FOXC1 genes.  Snai1, PLAU, SOX9 and FOXC1 gene expression is not synergistic 
in combined drug treatment (DT) condition. PLAU gene is TNFα responsive only, whereas EDN2, 
NPPC and EGR and highly doxorubicin responsive and reveal transcriptional synergy upon combined 
treatment (DT). * p-value <0.05 for the comparison between single and double treatment for the 
indicated genes (Student’s t-test) 
In p53 null H1299 cells, the synergy was absent, suggesting that transcriptional synergy is a 
p53-dependent phenomenon (see Figure 6 in paper attached in Appendix). We tried to 
recapitulate p53 and NF-кB cooperation in H1299 cells after ectopic expression of wild type 
p53. While p53 overexpression led to activation of p53 target genes such as p21 and PUMA, 
treatment with doxorubicin did not further stimulate the transcription. Perhaps consistently, no 
synergistic expression of signature genes (ETV7, LAMP3, NTN1, UNC5B and PLK3) was 
observed.  
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   p21 (CDKN1A)   PUMA (BBC3) 
              
Figure 19: p53 transcriptional targets p21 and PUMA are expressed in p53 transfected H1299 
cells. H1299 cells are transfected with low amount of p53 expressing plasmid as well as empty vector 
and quantified for the expression of p21 and PUMA genes using qPCR.  Further Treatment of cells 
with Doxorubicin (DOXO), TNFα (TNF) and Doxorubicin + TNFα (D+T) does not impact the 
transcription of two genes. 
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2.2.2 Combined Doxorubicin and TNFα treatments reduce migration potential of A549 
cells, but enhance the migration of p53 null H1299  
Cell migration tests for A549 and H1299 cells were performed both using an xCELLigence  
Real Time Cell Analyzer (RTCA) and a Transwell Migration assay Kit (Figure 20). As 
previously done for MCF7 cells (see Appendix) both A549 and H1299 cells were treated for 
16 hours with Doxorubicin and TNFα individually or combined. Cells were then collected to 
start migration assays according to manufacturer’s protocol (see Materials and Methods). I 
observed that treatment of cells with TNFα alone enhances the migratory phenotype of A549 
cells (more visibly in transwell migration assay, see Figure 20 E). Treatment of cells with 
Doxorubicin alone reduced the migration by 50% and the combined doxorubicin and TNFα 
treatment reduced the stimulatory effect of TNFα treatment in A549 cells. On the other hand 
all treatments and particularly the combined one increases H1299 migration. This suggests 
that the impact of chemotherapeutic agents is cell line specific and that the synergistic 
expression of the identified signature genes cannot be directly correlated with cell migration 
in vitro. At the same time, the treatment of p53 null cells with chemotherapeutic agents in the 
presence of inflammatory signals can alter tumour aggressiveness. Next, we ectopically 
expressed p53 (with a low amount of transfected plasmid, 200ng for 5x10
5
 seeded cells) in 
H1299 cells to check whether migratory phenotype is affected by p53 expression. As a 
control, empty pCI-Neomycin vector was transfected. In RTCA experiment, I observed that 
p53 expression reduces the H1299 migration by 40% but the effect of treatments was not very 
different from the mock condition in the presence of p53 (see Figure 20 C, D). In transwell 
migration assay, the treatments further lowered the migration potential of the p53-expressing 
H1299 cells (Figure 20 F). Expression levels of p65, p53 and p21 proteins were measured in 
transfected H1299 cells upon all the treatments conditions (Figure 21). The p53 transfected 
H1299 cells express p53 as well as p21 under treated as well as untreated condition, whereas 
empty H1299 is null for the expression of p53 while the expression of p21 is slightly 
increased by the treatments but very weak. The expression of p65 is uniform in all cases.  
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Figure 20: Real time cell migration and Transwell migration analysis. (A, B, C, D) A549, H1299, 
empty and p53 transfected H1299 cells in (Mock), Doxorubicin (DOXO), TNFα (TNF) and 
Doxorubicin+TNFα (DOXO+TNF) treated conditions are loaded in equal numbers (four biological 
replicates) on CIM-16 plates for real time analysis of cell migration till 40-100 hours. Equal number of 
untreated and treated (E) A549 cells (F) Empty and p53 expressing plasmid transfected in H1299 cells 
are also loaded in transwell migration plate (three biological replicates) for eight hours to observe the 
migration. * p-value <0.05 for the compared bars expressing p53 alone or coupled with TNFα 
treatment (Student’s t-test). # Statistically non-significant differences between single or double 
treatments. In A549 TNFα significantly stimulated migration and doxorubicin as single agent or 
combined with TNF repressed migration. 
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2.2.3 Impact of Myst family members (HATs), MOF and TIP60 on p53 and NF-кB 
transcriptional targets in MCF-7, A549 and H1299 cell lines. 
TIP60 and MOF are known regulator of both p53 and NF-кB transcription activity and 
important hallmarks of tumour. Also, they work in combination with various other cofactors 
like p300 and CBP in gene regulation (178-180). I wanted to investigate if ectopic expression 
of TIP60 and MOF contributes in altering the Doxorubicin and TNFα mediated transcription 
of signature genes (ETV7, LAMP3, NTN1, PLK3 and UNC5B). A549 cells were transfected 
with plasmids expressing TIP60 and MOF, respectively, followed by 16 hours treatment with 
doxorubicin and TNFα individually and combined. Post treatment, RNA extraction and RT-
qPCR was performed on genes of interest (see Materials and Methods). I observed that TIP60 
or MOF expressing cells reveal enhanced transcription of ETV7, NTN1 and LAMP3 in a 
Doxorubicin-dependent manner in comparison to the cell transfected with empty vector and 
then treated. Also, TIP60 expression reveals some inhibitory effect on TNFα-dependent 
transcription of ETV7, NTN1, LAMP3 and PLK3 in A549 cells (Figure 22). No significant 
effect of TIP60 and MOF on transcription of p21 gene was observed (Figure 23), suggesting 
doxorubicin-dependent specificity of the two proteins towards our genes of interest. On the 
other hand, the NF-кB target MCP-1 was down-regulated upon TNFα treatment of MOF- and 
particularly TIP60-transfected A549 cells, revealing the two HATs as potential negative 
regulators on NF-кB in A549 (Figure 23). 
Figure 21: Protein expression in H1299 
cells transfected with p53 or empty 
expression vectors. Transfected cells 
were also treated with Doxorubicin 
(Doxo), TNFα (TNF) and Doxorubicin+ 
TNFα (D+T) or left untreated (Mock) and 
proteins were extracted to quantify the 
expression of p65, p53 and p21 for all 
conditions. GAPDH protein expression is 
used as a loading control 
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Figure 22: TIP60/MOF mediated gene regulation in 
A549 cells in treatment dependent manner. qPCR is 
performed for ETV7, NTN1, UNC5B, LAMP3 and 
PLK3 genes with total RNA extracted from MOCK, 
Doxorubicin (DXR), TNFα and Doxorubicin+TNFα 
(DT) treated TIP60 or MOF expressing A549 cells. 
Empty plasmid is transfected as control and treated for 
all conditions. The quantification is calculated as Fold 
change over empty mock for each case. 
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Figure 23: Impact of HATs (TIP60 and MOF) overexpression on transcription of p21 and MCP-1 
in A549 cells.  qPCR analysis reveals no impact of TIP60 and MOF an transcription of p21 with or 
without treatment.  TIP60 and MOF expression reduces MCP-1 transcription in TNFα-dependent manner. 
 
MCF7 cells upon TIP60 overexpression reveal enhanced transcription of signature 
genes. 
Over-expression of TIP60 in MCF7 cells up regulates the transcription of signature genes in 
the mock condition (Figure 24). This could be due to the relaxed chromatin state induced 
upon TIP60-mediated histone acetylation (181). The p21 gene expression is upregulated in 
Doxorubicin+TNFα treatment condition, whereas the NF-кB target MCP-1 exhibits TNFα-
dependent up regulation in TIP60 overexpressing MCF7 cells (Figure 25). Unlike the case in 
A549, the LAMP3 and ETV7 signature genes are not negatively regulated by TIP60 ectopic 
expressing in MCF7 cells treated by TNFα. 
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Figure 24: Impact of TIP60 
overexpression on signature gene set 
in MCF7 cells. TIP60 overexpression 
in MCF7 elevates the transcription of 
signature gene set. Treatment of TIP60 
expressing cells with Doxorubicin 
(DXR), TNFα and both (DT) does not 
enhance the transcription any further. 
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Figure 25: Impact of TIP60 overexpression on p21 and MCP-1 in MCF7 cells. TIP60 
overexpression slightly enhances the p21 transcription upon combined treatment (DT) condition in 
TIP60 dependent manner. A slight increment in MCP-1 expression is observed in TIP60 expressing 
cells upon TNFα treatment. 
 
Doxorubicin and TNFα combined treatments in p53 null H1299 ectopically expressing TIP60 
reveal a striking synergistic expression of ETV7, LAMP3 and PLK3. Also, expression of 
TIP60 up regulates the transcription of genes in TNFα dependent manner (Figure 26). 
Treatment of cells with Doxorubicin alone does not induce responsiveness, suggesting TNFα 
induced signalling as a prerequisite for transcription modulation in this case. Also, one can 
say that transcriptional synergy observed for ETV7, LAMP3, and PLK3 genes is not really a 
p53-specific phenomenon for all cell types. 
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Figure 26: H1299 cells expressing TIP60 
exhibit transcriptional synergy for ETV, 
LAMP3 and PLK3 genes. TIP60 is 
expressed in p53 null H1299 cells and 
quantified with qPCR for ETV7, LAMP3 
and PLK3 gene expression in untreated (M), 
Doxorubicin (DXR), TNFα and 
Doxorubicin+TNFα (DT) condition. 
Moderate TNF-α mediated responsiveness 
for three genes is observed but dual (DT) 
treatment leads to transcriptional synergy for 
all three genes 
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2.2.4 Studying Doxorubicin + TNFα transcriptional synergy with defined promoter 
fragments from signature genes. 
Approximately, 1-1.5 kb long promoter or enhancer regions of eight synergistically 
upregulated genes carrying variably organized non canonical p53 and NF-кB REs were 
selected for cloning upstream of a Firefly luciferase cDNA in pGL4.26 vector, All the REs 
analysed using TRANSFAC database (http://www.gene-regulation.com/pub/databases.html) 
scored a cutoff value above 0.9, but no information was available regarding their 
transactivation potentials. Most of the promoter/enhancers carried two to three noncanonical 
NF-кB REs which were 8 to 10 nucleotides in length. The p53 REs ranged from half to 
quarter (3/4
th
) sites with mismatches in purine and pyrimidine flanks at various positions (see 
Table 7 in the Materials and Methods section).  
I wanted to evaluate if features like proximity between p53 and NF-кB cis elements in human 
genome and their closeness to transcription start site (TSS) of selective genes (signature genes 
in our case) can hold some significant impact on transcriptional outcomes. Another target was 
to find if such REs can synergize with each other at transcriptional level upon doxorubicin and 
TNFα treatments of cells. Out of eight reporter clones we constructed, five were tested in a 
preliminary analysis: NTN1, ETV7, LAMP3, DUSP5 and EDN2. The organization of p53 and 
NF-кB REs in promoter or enhancer region of the genes is described in Figure 17 (see the 
Materials and Methods section). All the clones were transfected in MCF7 cells and an empty 
pGL4.26 vector was used as control. Our results clearly suggest that the identified p53 cis 
elements are active as the cloned constructs were responsive to Doxorubicin treatment with 
the exception of DUSP5. On the contrary, all constructs were unresponsive to TNFα treatment 
suggesting that the NF-кB sites are inactive or not sufficient for transactivation in this type of 
assay. The combined treatment (Doxorubicin+TNFα) of cells show rather a decline in the 
luciferase activity in comparison with the Doxorubicin treatment alone, consistent with the 
lack of effect of TNFα alone (Figure 27). This observation also falls in line with the 
conventional view of NF-кB being an antagonistic player in p53-mediated regulation. The cis 
regulatory regions of all the tested genes when explored for their transcriptional activities in 
extra chromosomal context do not impart much information regarding the rules of 
transcriptional synergy, but hint towards the presence of context-dependent complex 
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molecular mechanisms responsible for a highly elevated gene expression upon 
chemotherapeutic treatments.  
 
Figure 27: Gene reporter assays evaluate treatment specific transactivation potential of NF-кB 
and p53 REs embedded in enhancer regions of five genes. Firefly luciferase activity in MCF-7 cells 
was quantified as a measure of treatment specific transactivation potential of each reporter clone type. 
Empty clone without any enhancer/promoter is used as a control and tested for all four conditions 
(mock, doxo, TNF, DT). Apparently, other than the empty, all other reporter clones exhibit some 
firefly luciferase activity even in mock condition. NTN1, ETV7, LAMP3 and EDN2 showed 
responsiveness upon doxorubicin treatments. TNFα treatment does not induce any responsiveness and 
rather show a repression in Firefly luciferase activity. Also, the combined DT treatment leads to 
reduced transactivation in comparison to doxorubicin treatment alone. 
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DISCUSSION 
 
It is quite evident that chemotherapeutic treatments in context of tissue type and tumor 
microenvironment can concomitantly alter signalling pathways, ultimately impacting on the 
epigenetic landscape and leading to broad changes in the transcriptome of cancer cells, which 
can result in vital differences in tumour behaviour in terms of viability, migration and 
invasiveness (155, 159). In the previous experiment performed in MCF7 cells synergistic 
upregulation of gene expression was revealed upon combined treatment with doxorubicin and 
TNFα and correlated with enhanced cell migration in vitro. That correlation was not confirmed 
in A549, where Doxorubicin repressed migration, although the addition of TNFα mitigated the 
Doxorubicin effect, resulting in higher relative migration potential. Furthermore in p53-null 
H1299 cells, the combined treatment had virtually no effect on the expression of selected 
signature genes, yet it led to a clear increase in migration. Combined, these results suggest that 
the identified genes are not critical determinants of cell migration in vitro. The ectopic 
expression of p53 in H1299 was an attempt to evaluate the role of this transcription factor on 
both signature gene expression and migration. The ectopic expression of low amounts of p53 in 
H1299 led to transcriptional activation of p53 target genes like ETV7, NTN1 and UNC5B. 
Although the treatment of p53 expressing H1299 cells with Doxorubicin and TNFα could not 
recapitulate the synergy. Also, p53-expressing H1299 cells showed a reduced migratory 
potential like A549 cells and the treatments further reduced the migration of the cells. While 
p53 levels can control cell migration behaviour, the virtual synergistic expression of signature 
genes cannot be directly correlated with the migratory behaviour of these cells.   
Various other cofactors and molecules are reported to modulate the interplay of p53 and NF-
kB in a context-dependent manner. Proteins like PI3 kinases, p38 and STAT3 regulate the 
transcriptional cross talk of p53/NF-кB at various signalling nodes to control the impact of 
inflammatory molecules on tumorigenesis. We decided to investigate the impact of epigenetic 
regulators like histone acetylases or methylases in remodelling the transcriptional landscapes. 
As a preliminary analysis, we tried to investigate if TIP60 and MOF histone acetyl transferases 
(HATs), which regulate both p53 and NF-кB, are involved in the transcription of our target 
gene set (ETV, LAMP3, NTN1, PLK3 and UNC5B). In A549, transfection of TIP60 and 
particularly MOF expression vectors led to small changes in the expression of a subset of the 
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genes by single treatments, but did not significantly modify the impact of the double treatment. 
In MCF7, TIP60 expression (MOF was not studied) led to dramatic upregulation of the genes’ 
transcription in mock condition, especially for ETV7, LAMP3 and NTN1, but did not further 
enhance the impact of double treatment. In p53 null H1299, where the impact of single 
treatment was weak, if at all visible, the TIP60 plasmid led to clear synergistic upregulation in 
the context of the double treatment. The emerging picture suggests that different subset of 
molecular players appear to be at play in the regulation of these genes. Given the potential 
impact on cancer cells of ETV7 or LAMP3 over expression (182, 183), in-depth mechanistic 
studies are needed to clarify their regulation. More experimental validation is required to 
establish a defined mechanism that leads to synergy in gene expression. Impact of cofactors 
like p300, STAT1, STAT3 and CBP in mediating synergistic expression of target genes is to be 
analysed as yet. Also, silencing of genes like ETV7 and LAMP3 is needed to know their 
impact on migratory phenotypes of the doxorubicin and TNFα treated cells. Additionally, the 
function of p53 isoforms like ∆133p53 is another intriguing aspect which has to be determined. 
Already it has been reported that p53 isoforms can lead to alterations in behaviour of cancer 
cells and rather impart oncogenic properties to different tissue types. As another exploratory 
aspect of this study, I have been trying to knock out p53 in MCF7 and A549 cell lines using 
CRISPR/Cas9 genome editing methodology to create isogenic p53 null cells to complement 
their p53-expressing counterparts used throughout the experiments.  
cis elements or REs are an important aspect of gene regulation and many studies suggest 
synergism between two non-canonical cis elements to activate the transcription of certain 
genes (77). For instance the ERα and p53 act synergistically to induce the expression of FLT1 
gene by occupying closely spaced REs in its promoter (98). The regulatory regions mapped in 
our study do not reveal any treatment-specific synergism in gene reporter assays, but we cannot 
entirely rule out their functionality as mediators of synergistic expression and the endogenous 
gene level. Studying the transactivation abilities of cis regulatory regions in genomic context is 
more informative due to direct involvement of long-range acting histone modifiers known to 
reprogram the chromatin landscape and regulate the expression of specific genes. The promoter 
and enhancer fragments we tested as non-genomic regulatory elements established that p53 
REs are more robust in nature and tolerate nucleotide mismatches at various positions whereas 
NF-кB REs are comparatively less active. Generally, NF-кB proteins work as transcription 
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factors in combination with various other cofactors such as SP1, AP1, STAT3, IRF/ATF etc.  
to initiate or modulate the transcription (184). It is quite possible that we were not able to 
include some crucial binding sites needed for NF-кB mediated gene activation in the tested 
promoter fragments. Also, we have shown that NF-кB binding sites function better as a 20mer 
sequence if exploited outside the genomic context (134).  In this regard, the cloning of 
promoter fragments to establish gene reporter assays revealed that such approach could not 
recapitulate the synergistic response to doxorubicin and TNFα, although it confirmed the 
doxorubicin responsiveness in p53 wild type cells. This may also suggest that if the 
contribution of NF-кB to the gene regulation is cis-element dependent, such sites would be 
distant from the putative p53 REs. 
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ABSTRACT
The p53 and NFκB sequence-specific transcription factors play crucial roles 
in cell proliferation and survival with critical, even if typically opposite, effects 
on cancer progression. To investigate a possible crosstalk between p53 and NFκB 
driven by chemotherapy-induced responses in the context of an inflammatory 
microenvironment, we performed a proof of concept study using MCF7 cells. 
Transcriptome analyses upon single or combined treatments with doxorubicin 
(Doxo, 1.5μM) and the NFκB inducer TNF-alpha (TNFα, 5ng/ml) revealed 432 up-
regulated (log2 FC> 2), and 390 repressed genes (log2 FC< -2) for the Doxo+TNFα 
treatment. 239 up-regulated and 161 repressed genes were synergistically regulated 
by the double treatment. Annotation and pathway analyses of Doxo+TNFα selectively  
up-regulated genes indicated strong enrichment for cell migration terms. A panel 
of genes was examined by qPCR coupled to p53 activation by Doxo, 5-Fluoruracil 
and Nutlin-3a, or to p53 or NFκB inhibition. Transcriptome data were confirmed for 
12 of 15 selected genes and seven (PLK3, LAMP3, ETV7, UNC5B, NTN1, DUSP5, SNAI1) 
were synergistically up-regulated after Doxo+TNFα and dependent both on p53 and 
NFκB. Migration assays consistently showed an increase in motility for MCF7 cells 
upon Doxo+TNFα. A signature of 29 Doxo+TNFα highly synergistic genes exhibited 
prognostic value for luminal breast cancer patients, with adverse outcome correlating 
with higher relative expression. We propose that the crosstalk between p53 and NFκB 
can lead to the activation of specific gene expression programs that may impact on 
cancer phenotypes and potentially modify the efficacy of cancer therapy.
INTRODUCTION
Cancer cells are continuously exposed to a number 
of signaling cues that reflect the distinct nature of the 
microenvironment at primary tumor site, metastastic 
lesions and potentially also during circulation in the blood 
stream [1–4]. Therapeutic intervention strategies can 
result in acute changes in microenvironment signaling, 
acting also through non-transformed cellular components 
resident at the primary tumor site [3, 5]. Cellular responses 
to changes in the microenvironment requires coordinated 
activation of sequence-specific transcription factors [6], 
among which NFκB and p53 have a prominent role and 
often opposing functions [7].
The p53 tumor suppressor gene is activated in 
response to a large number of cellular stress signals, 
including genotoxic stress, carbon and oxygen 
deficiencies, excessive proliferation signals [8, 9]. 
There are >150 established p53 target genes that link 
p53 to many different biological outcomes [10–14]. 
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The NFκB family of sequence-specific transcription factors 
consists of essential regulators of immune, inflammatory, 
proliferative and apoptotic responses [15], and their 
activation generally results in the onset of pro-survival 
signals [16]. The most common form of the NFκB complexes 
is the p50/RELA (p65) heterodimer. p53 and NFκB 
activation occurs simultaneously in response to diverse 
stress conditions, including genotoxic stress and NFκB 
proteins are frequently de-regulated in cancer, resulting in 
constitutive activation [17]. Competition between p53 and 
NFκB for a common limiting cofactor such as p300 can 
result in mutual inhibition [17, 18]. However, examples of 
positive interactions have also been reported. For example, 
it was shown that p65 can induce the p53 target gene p21 by 
direct binding to its promoter [19] and participates in p53-
dependent apoptosis [20]. Several human Toll-like receptors 
(TLRs), whose signaling leads to NFκB activation [21], 
were identified as direct p53 target genes both in cancer cells 
and primary cells [22] and it was demonstrated that p53 and 
NFκB can cooperate in the activation of pro-inflammatory 
genes in primary human monocytes and macrophages [23].
To investigate more globally the transcriptional 
crosstalk between p53 and NFκB we performed a proof 
of concept study using breast cancer-derived MCF7 
cells treated with Doxorubicin, Tumor Necrosis Factor 
alpha (TNFα) and a combination of the two compounds 
(Doxo+TNFα). Our results demonstrated a synergistic 
interaction between p53 and NFκB transcription factors, 
which can lead to the reprogramming of cell fate and 
enhanced migratory potential. Seven genes (PLK3, 
LAMP3, ETV7, UNC5B, NTN1, DUSP5, SNAI1) 
were established as synergistically up-regulated after 
Doxo+TNFα and dependent both on p53 and NFκB. A 29-
gene signature of highly synergistic genes up-regulated 
by Doxo+TNFα appeared to have prognostic value in a 
cohort of luminal breast cancer patients [24].
RESULTS
Striking transcriptome changes upon the 
combination of Doxorubicin and TNFα treatment 
of MCF7 cells
We first investigated the potential crosstalk between 
Doxorubicin (Doxo) and TNFα treatment using gene 
reporter assays in the human breast adenocarcinoma-
derived MCF7 cells (Figure S1A). p53-dependent 
responsiveness of the P21 and MDM2 promoter plasmid 
constructs was observed following Doxo treatment and 
confirmed by p53 silencing. The transactivation of the 
P21 and MDM2 constructs was reduced upon addition 
of TNFα to Doxo, suggesting possible inhibition of p53 
activity by NFκB. Mutual inhibition of the p53 and p65/
RELA proteins has been previously shown on p21 [17], 
while both inhibition and cooperation were reported at the 
BAX gene [18, 20]. However, this effect was not observed 
at the level of the endogenous P21 and MDM2 genes 
(Figure S1B), which showed similar level of activation 
in response to either Doxo alone or Doxo+TNFα. An 
NFκB reporter construct was responsive to both Doxo and 
TNFα as single treatments and showed a strong increase 
following the double treatment that was unaffected by 
p53 silencing. On the contrary, the endogenous TNFα 
and MCP1 NFκB target genes were weakly responsive 
to Doxo alone, highly induced by TNFα treatment, 
and showed intermediate induction levels upon double 
treatment. Hence, canonical p53 or NFκB target genes 
did not exhibit synergistic transcriptional responses to the 
combined treatment with doxorubicin and TNFα.
Next we performed a genome-wide transcriptome 
analysis after Doxo, TNFα, or the combination of the 
two compounds using the Agilent 4 × 44k array and 
single color labeling. Differentially expressed genes 
(DEGs) were selected based on rank product test, 
setting a threshold of 0.05 on the percentage of false 
positives (pfp) and a threshold of 2 on the absolute log2 
fold changes. The double treatment more than doubled 
the number of DEGs (Figure 1). The vast majority 
of DEGs resulting from the single treatments were 
also differentially expressed in the double treatment. 
Gene Ontology (GO) as well as pathway and upstream 
regulators analyses (DAVID, http://david.abcc.ncifcrf.
gov/; IPA, http://www.ingenuity.com/) confirmed 
activation of p53 signaling upon Doxo treatment as 
most significant pathway, and apoptosis induction 
as the most significantly enriched GO terms among 
up-regulated DEGs (Figure 1A-C). TNFα treatment 
also resulted in gene annotation terms consistent with 
NFκB activation, such as regulation of T cell activation. 
The gene annotation of DEGs resulting from the double 
treatment was enriched for terms typical of the two 
single treatments (e.g. T cell activation and apoptosis 
regulation among the up-regulated DEGs). TP53 as an 
upstream regulator was less significant in the double 
treatment compared to the Doxo single treatment, while 
p65/RELA, NFKBIA, IRF7 and STAT1 appeared to 
be even more enriched in the double treatment compared 
to TNFα single treatment (Figure 1B). The double 
treatment not only led to a higher number of DEGs, but 
resulted in quantitative differences in gene expression 
levels compared to the single treatments. We applied a 
rigorous filter and identified 212 repressed, 361 induced 
DEGs that were synergistically regulated by the double 
treatment Doxo+TNFα (see Methods) (Figure 1D). 
Notably, this subgroup of up-regulated DEGs was 
enriched for cell migration GO biological process 
along with the expected canonical terms for p53 and 
NFκB. Collectively, our systematic analysis indicates 
a vast network of genes that can be mutually affected 
by combined activation of p53- and NFκB-dependent 
responses.
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Doxorubicin + TNFα transcriptional synergy 
identifies new direct p53 and NFκB target genes
We selected fifteen genes for validation experiments 
based on (a) statistical analysis of synergistic up-regulated 
DEGs, (b) prior knowledge on direct regulation by either 
p53 or NFκB, (c) availability of ChIP-seq data for both 
transcription factors, and (d) gene functions in relation to 
cancer biology. The selected list contains genes encoding 
players of the control of various cellular processes, 
e.g. cell proliferation (PLK3, DUSP5, PLAU, GBX2, 
ETV7, EDN2), apoptosis (TNFRSF10B, UNC5B), 
inflammation (LAMP3, EGR2), development (GBX2, 
SOX9, NPPC, FOXC1) and cell migration (SNAI1, 
PLAU, UNC5B, NTN1, EDN2).
For twelve of the 15 genes we confirmed a 
synergistic response to the Doxo+TNFα treatment by 
qPCR (Figure 2A). Most of them were independently 
reported as putative targets of either p53, p65 or both 
according to published ChIP-seq data (for p65, http://
genome.ucsc.edu/ENCODE) [14, 25]. A potential direct 
contribution of NFκB on the observed gene expression 
Figure 1: A vast array of genes responds selectively to Doxorubicin and TNFα in MCF7 cells. (A) Number of DEGs 
identified after single or combined treatment (see Methods for statistical filters). Most significant gene ontology terms of down- or 
up-regulated DEGs, according to DAVID (http://david.abcc.ncifcrf.gov). (B) Predicted upstream regulators of the DEGs for the indicated 
treatments, according to IPA (IPA, http://www.ingenuity.com). The color code reflects the enrichment or depletion of the listed transcription 
factors targeting the DEGs from the array analysis. (C) Statistically relevant pathways predicted to be modulated in response to the 
indicated treatments according to IPA. (D) Number of DEGs that are synergistically regulated by the double treatment according to two 
different statistical filters (see Materials and Methods). The most significant gene ontology terms are also indicated.
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changes was evaluates using the small molecule 
inhibitor BAY 11–7082 (BAY) used as single agent or in 
combination with Doxo or/and TNFα (Figure 2B). Eight 
of the twelve validated synergistic DEGs were tested 
and for five of them BAY markedly inhibited the effect 
of Doxo+TNFα, or of TNFα alone. TNFα treatment led 
to higher levels of nuclear p65, while Doxo alone or in 
the combined treatment did not significantly impact p65 
nuclear protein levels. BAY treatment led to a slight 
reduction of p65 nuclear levels, which was paralleled 
by an increase in the cytoplasm (Figure 2C). p53 protein 
levels were induced to similar levels by the different 
treatment combinations (Figure S2).
The five genes that showed more convincing 
p65 dependence on the synergistic response to 
Doxo+TNFα (PLK3, NTN1, UNC5B, ETV7, LAMP3) 
were investigated more deeply to establish a direct role 
of wild type p53 in their transcription. MCF7 cells were 
treated with the chemotherapeutic agent 5-Fluorouracil 
(5FU) or with the MDM2 inhibitor Nutlin-3a, alone or in 
combination with TNFα. Both p53-inducing molecules 
were at least additive with TNFα in the responsiveness 
of the five genes (Figure 2D). Although the magnitude 
of the synergistic response was higher with Doxo, the 
fact that three different p53-activating treatments led 
to up-regulation of these five genes strongly suggested 
a direct role of p53. We next employed an MCF7 clone 
with stable knock-down of p53 and the HCT116 p53-/- 
cell line, to further establish p53-dependence of the five 
genes expression upon Doxo treatment. Matched MCF7 
vector and HCT116 p53+/+ were used as a comparison 
(Figure 2E, F). Invariably, Doxo responsiveness was 
strongly reduced in the p53-defective cells. Previous 
reports in the literature demonstrated or suggested p53-
dependent regulation of PLK3, NTN1 and UNC5B. Our 
results confirm those findings and establish, for the first 
time, the possibility of synergistic regulation by NFκB. 
PLK3, a polo-like kinase, is an important regulator of 
the cell cycle and it is involved in the control of hypoxia 
signaling pathway [26]. NTN1 is ligand for both DCC1 
and UNC5B receptors whose signaling can potentially 
modulate p53 activity, impacting on the decision between 
cell survival and cell death [27]. LAMP3 is a lysosomal 
membrane associated protein important in dendritic 
cells and potentially involved in tumor invasion [28], 
while ETV7 is a transcription factor associated to cell 
proliferation and tumorigenesis [29].
Given the lack of definitive evidence for LAMP3 
and ETV7 being direct p53 targets and since our finding 
of synergistic responsiveness, we examined p53 and 
(Continued )
Figure 2: p53- and p65-dependent up-regulation of selected synergistic DEGs. (A) Twelve out of fifteen selected synergistic 
DEGs were validated by qPCR. Plotted are the average fold change relative to the mock condition and three reference genes (GAPDH, 
B2M, ACTB) and the standard deviations of three biological replicates. “^” marks genes responding in synergistic manner to the double 
treatment. p53 and p65 occupancy data from available ChIP-seq datasets are summarized below each gene name. (B) Impact of the NFκB 
inhibitor BAY 11-7082 on the synergistic gene expression response plotted as in panel A. “*” Significant inhibition of by BAY when 
combined to Doxo + TNFα (t-test, p<0.01). NPPC and SNAI1 were also tested but their expression levels were not affected by BAY 
treatment. 
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p65 occupancy in MCF7 cells treated with Doxo or TNFα 
(Figure 3). p53 occupancy was detected both for ETV7 
and LAMP3 as well as for the positive control P21, in 
Doxo treated cells. For ETV7 p53 occupancy appeared 
to increase also after TNFα treatment. P21 was the only 
target for which p53 appeared to be bound also in the 
mock condition, a result consistent with previous data 
[30]. p53 occupancy levels were not distinguishable 
between Doxo and Doxo+TNFα treatment.
Both LAMP3 and ETV7 exhibited p65 occupancy in 
TNFα treated cells, although to a lower extent compared 
to the positive control MCP1. For the three promoter 
regions, occupancy was increased also by Doxo treatment 
alone, but no additive effect of the double treatment was 
apparent, except for a trend with LAMP3. On the contrary 
lower occupancy at MCP1 was detected in double treated 
cells. This latter result is consistent with the MCP1 mRNA 
expression changes (Figure S1B).
Hence, we identified genes whose expression is 
co-regulated by Doxo and TNFα. The gene expression 
studies conducted with different p53-activating molecules, 
the use of cells lines with different p53 status, and the 
chromatin immune-precipitation studies collectively 
established a direct role for p53 and p65 on the 
transcriptional regulation of PLK3, NTN1, ETV7, UNC5B 
and LAMP3. However, we did not find a direct correlation 
between occupancy levels at predicted promoter binding 
sites and gene expression changes.
Figure 2: (C) p65 nuclear (NE) and cytoplasmic (CE) relative protein levels under the different treatments used in panel B. M = mock; 
D = Doxo; T = TNFα; B = BAY. Proteins were fractionated as described in Materials and Methods. GAPDH and histone 3 (H3) served 
as controls for cytoplasmic and nuclear fraction respectively. As controls, a cytoplasmic mock fraction sample (CE) is loaded together 
with the nuclear proteins and vice versa a nuclear mock sample (NE) in included in the cytoplasmic blot. (D) 5-fluorouracil and Nutlin-3a 
induced expression of 5 selected DEGs alone or in combination with TNFα. Results were obtained and are plotted as in A. (E), (F) The 
relative expression of the 5 selected genes shown in panel C was tested in doxorubicin treated matched cell lines differing for p53 status 
(MCF7 vector and shp53, D; HCT116 p53+/+ and p53-/-, E).
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Doxorubicin + TNFα treatment enhances the 
migration potential of MCF7 cells
Both the gene ontology enrichments of synergistic 
DEGs and the known function of the fifteen genes chosen 
for validation suggested the possible activation of gene 
expression programs influencing cell motility, epithelial 
mesenchymal transition (EMT) or even stem-like 
phenotypes. Projected to an in vivo context, the crosstalk 
of signals present in an inflammatory microenvironment 
could have a negative impact on the efficacy of 
chemotherapy, possibly by enhancing tumor cell plasticity. 
To begin exploring this hypothesis, we investigated 
migration and invasion potential of MCF7 cells treated 
with Doxo, TNFα or both. Three different experimental 
approaches consisting in real-time cell migration analysis 
(Figure 4A), transwell migration test (Figure 4B) and 
wound healing assay (Figure 4D) consistently showed 
higher migration potential of double-treated MCF7 cells, 
while the invasion phenotype was unaffected by all three 
types of treatment (Figure 4C).
Several studies suggest that EMT not only enhances 
the motility and invasiveness of cancer cells, but also 
provides additional aggressive features such as stemness 
and therapeutic resistance [31]. Indeed, several of the 15 
synergistic DEGs we validated are directly or indirectly 
associated with acquisition of stem-like phenotypes in 
normal or cancer cells, particularly SNAI1 [32, 33], 
SOX9 [34] and GBX2 [35]. Different lines of evidence 
indicate that breast cancer stem cells (BCSCs) display 
increased cell motility, invasion, and overexpress genes 
that promote metastasis [36] and can be traced by CD44+/
CD24-/low surface marker expression [37]. We asked if 
the Doxo+TNFα treatment could enhance the stem-like 
subpopulation of the MCF7 cell line (Figure 4E). FACS 
analysis showed that the CD44+/CD24- subpopulation 
virtually disappeared after all treatments. Therefore, the 
higher motility observed upon double treatment cannot be 
directly related to the expression of these surface markers, 
hence to putative stem-like features.
Prognostic value of Doxorubicin + TNFα 
synergistic DEGs
Since luminal type breast cancer, of which MCF7 
is considered as a model, frequently retains wild type 
p53 and NFκB responsiveness, we asked if Doxo+TNFα 
synergistic DEGs could be endowed with prognostic 
significance. Up-regulated DEGs were further filtered 
by selecting genes that were strongly responsive to the 
double treatment but minimally responsive to the single 
ones (see Materials and Methods). A signature list of 
Figure 3: Occupancy analysis establishes ETV7 and LAMP3 as direct p65 and/or p53 target genes. (A) Relative 
quantification of immune-precipitated gene fractions by qPCR from MCF7 cells subjected to Doxo or TNFα single treatments and to the 
double treatment. The antibodies used for the immune-precipitations are listed. P21 was used as positive control, while ACTB was used 
as a negative control. Plotted are the average percentages relative to input signals. Error bars represent the standard errors of at least three 
biological replicates. (B) as in A, but probing p65 occupancy. MCP1 was used as positive control. The IgG antibody controls were anti-
mouse (A) or anti-rabbit (B) to match the specific primary antibodies. (C) The position of the primers used for the qPCR and the location 
of predicted p53 and p65 binding sites in the ETV7 and LAMP3 genes are depicted.
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Figure 4: Doxo+TNFα leads to enhanced MCF7 motility but ablates the stem-like side population. (A) Real-time migration 
assays examined by xCELLigence. Plotted are the average results of four biological repeats. Cell Index is proportional to the number of cells 
migrating through a hole in the culture plate. The treatments relative to the different curves are indicated. (B) Relative transwell migration 
values quantified by a fluorescence readout (see Materials and Methods). Average and standard deviation of triplicate biological replicates are 
presented. The applied treatments are listed on the x-axis. (C) As for B, but measuring the invasion potential of MCF7. (D) Images of a wound 
healing assay obtained at T0 or T24. Composite (3×3) images were acquired using an automated Zeiss microscope and the AxioVision3.1 
software. (E) Cell sorting results based on intensity of CD44 and CD24 surface markers on 30000 cells. Q1 individuates the CD44+/CD24-(low) 
cells, considered as stem-like. The percentages in the four quadrants after the various treatments are presented in the table.
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29 genes (DT29) was generated (Figure 5A) and used to 
interrogate clinical data using the KM plotter tool [38]. 
Interestingly, breast cancer patients with luminal type A 
diagnosis who underwent chemotherapy and exhibited 
higher relative expression of DT29 genes showed poorer 
prognosis (Figure 5B). The same was true for luminal A 
patients with lymph node infiltration or luminal A grade 2 
(Figure 5C, D).
Analysis of Doxorubicin and TNFα crosstalk in 
lung cancer-derived and HUVEC cells
We extended our analysis to another pair of cancer 
cell lines that differ for p53 status. A549 (p53 wild type) 
and H1299 (p53 null) lung cancer derived cells were 
treated with Doxo or/and TNFα or/and BAY. Expression 
of PLK3, NTN1, ETV7, UNC5B and LAMP3 was 
measured by qPCR (Figure 6A-E). The impact of the 
various treatments on p65 nuclear and cytoplasmic, p53 
and p21 protein levels was also evaluated (Figure 6F, 6G). 
In the p53 null H1299 cells the relative expression changes 
of all the genes was invariably much lower compared to 
A549 cells. However, NTN1 was weakly TNFα inducible 
and ETV7 was weakly Doxo+TNFα responsive. Instead in 
A459 cells NTN1, ETV7 and LAMP3 were synergistically 
up-regulated by Doxo+TNFα, while PLK3 and UNC5B 
were additive. The magnitude of induction upon Doxo 
was often one order of magnitude higher compared 
to TNFα alone. Transient transfection assays with the 
κB luciferase reporter construct were performed using 
different concentrations of TNFα or BAY (Figure S3). 
Based on the results, 10ng/ml TNFα and/or 20μM BAY 
were chosen for the qPCR experiments, although the 
reduction of TNFα-induced reporter activity was modest, 
albeit significant. At the endogenous gene level in A549 
cells we did not observe the inhibitory effect of BAY on 
either TNFα-induced changes or Doxo+TNFα, with the 
possible exception of UNC5B (Figure 6A-E). However, 
BAY treatment reduced the Doxo responsiveness of these 
genes, which might be dependent on its effect on the 
activation of NFκB by endogenous production of TNFα. 
In the p53 wild type A549 cells, p53 and p21 protein 
levels were induced by Doxo and not affected by the 
treatment with TNFα. Total p65 levels were unaffected 
by all treatments in both cell lines (Figure 6F). Nuclear 
p65 protein levels were increased in response to TNFα or 
Figure 5: Prognostic significance of a 29-gene list of synergistic Doxo+TNFα DEGs. (A) Top list of 29 genes (DT-29) 
exhibiting minimal responsiveness to Doxo or TNFα as single agents, but strong synergy upon combined treatment. A heat map view of 
the gene expression results is presented (see Materials Methods for statistical filters). Occupancy of both for p65 and p53 in the vicinity 
of the transcription start sites of these genes has been summarized from ChIP-seq data available in the literature. (B-E) Kaplan-Meier 
plots stratifying a breast cancer patient cohort based on the relative expression of the DT-29 gene list and relapse free survival. Graphs 
were generated with the KM-plotter tool (ref). Patients’ numbers are listed below the graph. Hazardous Ratio and the statistical analysis is 
reported for selected patients subgroups: (B) luminal A patients who underwent chemotherapy treatment (n = 111); (C) luminal A patients 
with a Grade 2 cancer at diagnosis (n = 385); (D) luminal A patients with lymph node infiltration at diagnosis (n = 447) and (E) the entire 
cohort of luminal A patients (n = 1509). Patients with a diagnosis of Luminal A breast cancer subtype were selected as the p53 status is not 
available in KM plotter, but this subgroup of breast cancer is expected to be strongly enriched for cases retaining wild type p53 protein.
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Figure 6: PLK3, NTN1, ETV7, UNC5B and LAMP3 responsiveness in lung cancer cell lines. (A-E) Relative fold change 
expression of the indicated genes and after the listed treatments in A549 (p53 wild type) and H1299 (p53 null) cells, measured by qPCR. 
Average and standard deviations of three biological replicates are presented. (F) Western blot of total p65, p53 and the p53 target p21. 
GAPDH was used as loading control. (G) Western blot of nuclear and cytoplasmic protein fractions were performed as for Figure 2C.
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Doxo+TNFα in both A549 and H1299 cells (Figure 6G). 
Interestingly, BAY treatment alone or in combination led 
to a reduction in p65 nuclear accumulation (Figure 6G).
HUVEC primary cells were also subjected to Doxo 
and TNFα single or double treatment and the expression 
of the same panel of five genes was tested by qPCR 
(Figure S4). Results among biological repeats varied, but 
in the majority of tests, all genes with the exception of 
LAMP3 were Doxo responsive; NTN1 and ETV7 were 
also TNFα responsive. No synergistic up-regulation by the 
double treatment could be consistently established. p53 
and p65 protein levels confirmed i) the activation of p53, 
with a similar level of p53 protein in the double treatment, 
and ii) the p65 proficiency of this cell line.
DISCUSSION
Wild type p53 functions are intricately related to 
multiple tumor suppressor pathways, primarily acting 
in cell autonomous manner to restrain cell proliferation 
and including cell death and senescence in response 
to genotoxic and many other types of cellular stresses 
[8, 9]. Furthermore, p53 also contributes to modulate 
the microenvironment in a non-cell autonomous 
manner [39]. p53 has also been linked to inhibition of 
EMT, for example through an indirect stimulation of 
E-cadherin expression [40]. At the same time, paracrine 
signaling in mice triggered by Doxorubicin were found 
to stimulate EMT and metastatic potential of cancer 
cells, in part through NFκB activation [3]. Many studies 
have highlighted the potential contribution of NFκB-
induced signaling in the acquisition of cancer cell traits 
conducive to chemoresistance and higher metastasis 
risk [2] [41]. While, the canonical functions of p53 and 
NFκB are consistent with the co-occurrence of p53 
inactivation and NFκB hyper-activation that is frequent in 
cancer [7], recent studies provided examples of positive 
cooperation between p53 and NFκB that would occur 
in specific cell types, such as antigen presenting cells or 
macrophages, and contribute to physiological responses, 
such as for example in the process of innate immunity and 
inflammation [12, 22, 23, 42].
Here we modeled the impact of a first line 
chemotherapeutic drug leading to genotoxic stress and 
p53 activation, using exposure to the immune cytokine and 
NFκB activator molecule TNFα as a variable, mimicking 
the effect of an inflammatory microenvironment. We 
used transcriptome analysis as primary endpoint and 
uncovered a vast network of differentially expressed 
genes that selectively responds to combined treatment 
with Doxorubicin and TNFα. Furthermore, genes that 
were synergistically up-regulated by both treatments 
appeared to endow cells with higher motility potential 
in vitro. Analyses of the annotated gene functions related 
to the aforementioned genes also revealed the possibility 
of an induced epithelial mesenchymal transition upon 
combination of the treatments. For example, SNAI1 
appeared to be regulated in more than additive manner 
by the double treatment, as well as LAMP3, a lysosomal 
protein previously associated with metastasis risk [28, 
43]. Multiple cytokines and secreted factors, including 
IL6, IL17, IL15 and its receptor, S100A8 and S100A9, 
CXCL12 and several Serpins were also identified as 
synergistic DEGs (Table S1). The presence of S100A8, 
S100A9 and CXCL12 among synergistic DEGs raises 
the possibility that, unlike the case of the triple negative 
cell line MDA-MB-231 for which S100A8-mediated 
signaling appeared to require heterotypic cell interactions 
[3] contributing to metastasis potential, in MCF7 cells 
this signaling could become homotypic or even autocrine. 
A marked difference in secreted factors and associated 
signaling among MDA and MCF7 cells was elegantly 
shown in recent studies [4].
A direct contribution of p65/RELA and p53 
in the observed gene expression changes elicited by 
Doxorubicin and TNFα was inferred for some of the 
synergistic DEGs by modulating pharmacologically or 
genetically p65 or p53 activities. However, we cannot 
exclude at this stage a (Doxo+TNFα)-dependent, but 
p53- or NFκB- independent gene expression changes. 
For example, NFkB can functionally interact with 
AP-1 [44–46] or ER [47], which in turn can modulate 
p53-dependent responses [48] [49] [50].
Among the most synergistic genes, 29 appear to 
be prognostic in luminal A breast cancer patients who 
underwent chemotherapy, where their higher expression 
correlated with adverse outcome. The majority of luminal 
A breast cancers are wild type for p53 [51], although data 
is not available to stratify patients for p53 status in the 
KM plotter tool [24]. Based on available ChIP-seq data 
[14, 25, 52, 53], 20 of these 29 genes are putative targets 
of either p53 or p65 and 10 of them are putative targets of 
both factors (Figure 5). This result raises the possibility 
of an unexpected negative outcome of chemotherapy in 
the context of an inflammatory microenvironment. The 
prognostic significance of this gene signature needs 
in-depth evaluation in independent patients cohorts. If 
confirmed, the results would further support the value 
of combining treatments activating p53 and repressing 
NFκB [7].
Given that the crosstalk between Doxorubicin 
and TNFα and the interplay between p53 and NFκB 
would occur in cells residing or infiltrating the tumor 
microenvironment, the ultimate in vivo outcome of these 
functional interactions may vary and cannot be directly 
predicted from our study using a pure culture of MCF7 
cells in vitro. Here we have explored Doxo+TNFα 
impact on HUVEC cells and also on a p53 wild type lung 
adenocarcinoma-derived cancer cell line. Although limited 
by the number of genes tested, the results suggest that a 
positive crosstalk between Doxorubicin and TNFα can 
be a general characteristic of different cell types and is 
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at least in part p53-dependent, based on the results with a 
p53 null lung cancer cell line. Furthermore, while we have 
addressed here the functional interactions between two 
small molecules, cells are constantly exposed to a complex 
milieu of signaling factors. However, both p53 and NFκB 
are master regulators, often contributing a dominant trait 
in gene expression changes to their target genes. Nuclear 
receptors, including Estrogen Receptors (ERs) can also 
modulate NFκB as well as p53 functions [54–56] and 
have critical roles in breast cancer etiology. We also 
explored the impact of ER function in the transcriptional 
programs responding to Doxorubicin and TNFα exposure, 
using estrogen-depleted culture conditions and adding 
17β-estradiol (10-9M, E2) as variable (Table S2 and GSE 
24065). However, the combination of E2 to Doxo and 
TNFα resulted only in 15 and 11 selective up- and down-
regulated DEGs, respectively (Table S3). A hierarchical 
cluster analysis of all the treatments confirmed graphically 
the large difference between TNFα- and Doxo-induced 
transcriptomes and also the significant impact of TNFα 
when combined to Doxo, while E2 had a minor effect both 
in the combination with Doxo and with Doxo + TNFα 
(Figure S5).
With this study we established an example of 
positive cooperation between p53 and NFκB, in the 
context of the responses of an epithelial cancer cell to 
standard chemotherapy but in the presence of active 
signaling by a pleiotropic inflammatory cytokine, such as 
TNFα. A signature gene of the consequent transcriptional 
reprogramming appears to be prognostic in breast cancer 
patients. Associated gene functions indicate the potential 
acquisition of enhanced cell plasticity and motility and 
provide a rationale to investigating mechanisms resulting 
in acquired chemoresistance, particularly for luminal A 
breast cancer, but potentially with general implication 
for p53 wild type tumors of different tissue types, and 
for overcoming such resistance by targeting NFκB. The 
unexpected positive crosstalk between p53 and NFκB 
emerging from our and other very recent studies [23] 
may represent an evolutionary consequence of anti-
viral and infection responses towards which NFκB is 
an established master regulator [57], but the p53 and 
p73 family member are emerging as important/critical 
contributors [42, 58, 59].
MATERIALS AND METHODS
Cell lines and culture conditions
MCF7 (p53 wild type, expressing p65 and positive 
for ERs) and HUVEC (Human Umbilical Vein Endothelial 
Cells) cells were obtained from ICLC (Genoa, Italy), while 
A549 from ATCC (Manassas, VA, USA). H1299 cells were 
a gift of Dr. Resnick’s laboratory (NIEHS, NIH, RTP, NC, 
USA); HCT116 p53+/+ and p53-/- of Dr. Vogelstein’s (John 
Hopkins Kimmel Cancer Center, Baltimore, MD, USA). 
MCF7-shp53 or control MCF7-vector cells were provided 
by Dr. Agami (Netherlands Cancer Institute, Amsterdam, 
The Netherlands). Cells were cultured in DMEM or 
RPMI media supplemented with 10% FBS, or Medium 
199 (Lonza Milan, Italy) supplemented with 50 units/
ml Low Serum Growth Supplements (Life Technologies, 
Milan, Italy) in the case of HUVEC cells that were also 
cultured on 0.1% gelatin pre-coated plastics. Media were 
supplemented by 2mM L-Glutamine and 1XPenicillin/
Streptomycin mixture (Pen/Strep), and Puromycin (0.5 μg/
mL) in the case of MCF7-shp53 and –vector cells. When 
appropriate, cells were maintained in DMEM without 
Phenol Red (Lonza) supplemented with Charcoal/Dextran 
treated FBS (Hyclone, GE Healthcare, South Logan, 
UT, USA).
Drug treatments
Doxorubicin (Doxo, 1.5 μM), 5-Fluorouracil (5FU, 
375 μM), Nutlin-3a (10 μM) were used to stabilize p53 
protein. When needed TNFα (5ng/ml in MCF7 and 10ng/
ml in H1299, A549 and HUVEC cells –based on dose-
response tests with gene reporter assays) or BAY11-7082 
(10μM or 20μM in H1299 and A549) were added to the 
culture medium. All compounds were from Sigma-Aldrich 
(Milan, Italy).
Microarray experiment and data analysis
Total RNA was extracted from 4 biological 
replicates using the Agilent Total RNA Isolation Mini Kit 
(Agilent Technologies, Santa Clara, CA, USA). Samples 
with RNA Integrity Number (RIN) above 9 (Agilent 2100 
BioAnalyzer) were processed. Details are provided with 
the Gene Expression Omnibus (GEO) (www.ncbi.nlm.
nih.gov/geo) submission (GSE24065) and in [56]. The 
output of Feature Extraction (Agilent standard protocol 
GE1_107_Sep09) was analyzed with the R software for 
statistical computing and the Bioconductor library of 
biostatistical packages. Probes with low signals were 
removed in order to filter out the unexpressed genes 
and keep only probes with acceptable signals in most 
of the replicates. Signal intensities across arrays were 
normalized by quantile normalization. Signal intensities 
from probes associated with the same gene were averaged. 
This procedure resulted in quantitative signals for 14095 
HGNC genes. To identify potential target genes of 
Doxorubicin and TNFα, we compared the signals after 
the double treatment (Doxo+TNFα) and the two single 
treatments relative to the untreated control (mock). 
DEGs were selected applying a statistical test based on 
rank products implemented in RankProd Bioconductor 
package, setting a threshold of 0.05 on the percentage of 
false positives (pfp) and a threshold of 2 on the absolute 
log2 fold changes [60]. Every treatment was compared to 
the mock condition (Table S1, S2 and Figure S5).
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To select genes with synergistic effect, i.e. genes 
whose expression variations were more than additive in 
the double treatment with respect to single treatments, a 
further comparison between the double treatment samples 
and all the remaining samples (single treatments and 
control samples) was performed (double treatment vs all). 
Synergistic DEGs were selected applying an additional 
pfp filter (pfp<0.005) derived from this comparison, to 
the list of DEGs resulting from the “double treatment 
vs mock” comparison. A more stringent criterion was 
obtained by calculating the synergistic effect (SE) of 
the double treatment as the observed difference between 
the fold change of the double treatment and the sum of the 
fold changes of the single treatments (SE=log2 FC double 
treatment – (log2 FC Doxorubicin + log2 FC TNFα). 
We filtered genes with SE>0 for up-regulated DEGs, 
SE<0 for down-regulated genes (Figure 1). To select 
genes where the up-regulation contribution of each single 
treatment was low respect to the up-regulation of the 
double treatment, the ratio of the single/double treatments 
was calculated, applying a 0.25 filter on them (FC 
Doxorubicin/FC double treatment <0.25 and FC TNFα/
FC double treatment <0.25) (see Table S1, S2).
RNA isolation and quantitative qPCR
Total RNA was extracted using Qiagen RNeasy Kit 
(Qiagen). cDNA was converted from 1 µg of RNA using 
M-MuLV reverse transcritptase and RevertAid cDNA 
Synthesis kit (ThermoFisher, Milan, Italy). qPCR was 
performed on a Bio-Rad CFX384 (Bio-Rad, Milan, Italy). 
TaqMan gene expression assays (Applied Biosystems, Life 
Technologies) and Probe MasterMix (Kapa Biosystems, 
Resnova, Rome, Italy) were used starting with 25ng of 
cDNA as previously described [56, 61]. GAPDH, B2M or 
ACTB served as reference genes.
Western blot
Protein extraction and immunodetections were 
performed as previously described [62], using ECL Select 
detection reagent (GE Healthcare) and anti-p53 (DO-1) 
anti-RelA/p65 (C-20) anti- p21 (C19), anti-GAPDH (6C5) 
(Santa Cruz Biotechnology, Heidelberg, Germany). When 
appropriate, nuclear and cytoplasmic fractionation was 
performed. MCF7, A549 and H1299 cell lines were seeded 
on 100mm Petri dishes and treated at 80% confluence 
with Doxo, TNFα, BAY or the combination of the drugs 
for 16 hours. Cells were harvested and cytoplasmic and 
nuclear proteins were extracted using NE-PER Nuclear 
and Cytoplasmic Extraction Kit (Pierce, ThermoFisher 
Scientific), following the instructions provided by the 
manufacturer. 20 μg of nuclear and cytoplasmic extracts 
were loaded on a 12% poly-acrylamide gel and transferred 
to nitrocellulose membranes. Antibodies used for detection 
were: anti-Histone H3 (clone #: ab1791, AbCam, Milan, 
Italy) and anti-Lamin A/C (clone #: 2032, Cell Signaling, 
Milan, Italy) used as nuclear loading control, and anti-
GAPDH used as cytoplasmic loading control.
Chromatin immunoprecipitation assay
We used previously described protocols [63, 64]. 
The following antibodies were used: anti-p53 (DO-1), 
anti-p65 (C-20) and IgG (sc-2025 or sc-2027) (Santa Cruz 
Biotechnology). ChIP-qPCR experiments were performed 
using Sybr MasterMix (Kapa Biosystems) and 2 μl of 
enriched DNA. Results were analyzed by the comparative 
Ct method (ΔCt) and normalized as % of input. Regions 
in the promoter of GAPDH or ACTB and p21 or 
MCP1 genes served as negative and positive controls, 
respectively. Primers were selected using Primer 3 
(http://primer3.ut.ee/).
Migration and wound healing assays
The migration potential of MCF7 cells was 
monitored by a real-time technique using the 
xCELLigence Instrument (Acea Biosciences, Euroclone) 
and CIM-16 plates, following manufacturer’s instructions. 
Prior to the analysis, cells were grown in estrogen-free 
medium for two days and left untreated (mock) or treated 
with Doxo, TNFα or the combination. 16 hours after 
the treatments, cells were detached and added to the top 
chamber in serum-free medium. Migration was detected 
every 10 minutes for 24 hours. We used 0.5% and 5% 
FBS as chemo-attractant. Migration and Invasion were 
also measured by QCMTM Fluor 24-Well Cell Migration 
and Cell Invasion kits (Merck-Millipore, Milan, Italy), 
according to manufacturer’s instructions. For wound 
healing, cells were seeded in 12-well plates and treated 
with Doxo, TNFα or the combination. After 16 hours a 
scratch was introduced using a 10 μl pipette tip. Images of 
the same field were acquired immediately (T0) and after 
24 hours (T24) using an automated Zeiss microscope and 
the AxioVision3.1 software in multidimensional mode 
with mosaic (3x3) acquisition.
Flow cytometry
MCF7 cells, seeded and treated as described 
above, were washed with PBS and harvested by 0.05% 
trypsin/0.025% EDTA. The cells were washed again 
with PBS containing 2% FBS before being subjected 
to antibody binding, a combination of fluorochrome-
conjugated monoclonal antibodies against human CD44 
(APC) and CD24 (FITC) or their respective isotype 
controls (BD Biosciences, Milan, Italy) and incubated on 
ice in the dark for 30 minutes. Cells were then washed 
twice with PBS/2% FBS and resuspended in PBS. Flow 
cytometry analysis was conducted using a FACSCanto II 
instrument (BD Biosciences).
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Supplementary Figure S1: Gene reporter and qPCR assays to probe p53 and p65 activity in MCF7 cells. (A) Gene 
reporter assays. To test p53 and NFκB responsiveness and effect of co-activation on reporter activity, MCF7 cells were seeded onto 
24-well plates 24 hours before transfection. 250ng of pGL3 promoter based reporters, containing portion of p21 and MDM2 promoter 
(harboring p53 response elements) or a p65 responsive repeat of kB responsive sequence plasmids, were co-transfected along with 50 ng 
of pRL-SV40 vector, to normalize for transfection efficiency. When appropriate, 25nM of siRNA double strand oligonucleotides (Qiagen, 
Milan, Italy) against human p53 (si-hp53) were added to the transfection mixture. A scramble siRNA with no match in human coding RNA 
(25nM) was used as control (Qiagen). Cells were transiently transfected using the HighPerFect transfection reagent (Qiagen). Twenty-four 
hours after transfection, cells were treated with Doxo (1.5 μM) increasing concentration of TNFα (1, 5, 10 ng/ml) and with a combination 
of the two compounds. Sixteen hours post-treatment cells were washed with PBS and lysed with Passive Lysis Buffer 1X and luciferase 
activity was analyzed using the Dual-Luciferase Reporter Assay System (Promega, Milan, Italy). MCF7 cells were transiently transfected 
with pGL3-based reporter vectors containing fragments of the p53 responsive MDM2 intron 1, p21 promoter or a p65 responsive repeat of 
kB response elements. A control vector expressing the Renilla luciferase was cotransfected to normalize for transfection efficiency. Short 
ds-RNA oligonucleotides targeting the p53 mRNA or a scramble control were also co-transfected. 24 hours after the transfection cells were 
treated as indicated. Dual luciferase assays were perfomed 16 hours after the treatment. Presented in the graph are the average relative light 
units and the standard deviations of three biological replicates. (B) qPCR assays. Relative changes in the expression of the P21, MDM2, 
TNFα, and MCP1 genes were measured by qPCR in MCF7 cells treated with Doxo (1.5 μM), TNFα (5 ng/ml) or the combination of the two 
drugs. mRNA was isolated 16 hours after treatment, as described in the Methods Section. Bars plot the average fold of induction relative to 
the mock condition and error bars plot the standard deviations of three technical replicates. The entire experiment was repeated two times 
with consistent results.
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Supplementary Figure S2: p53 and p65 protein levels in MCF7 cells treated with Doxo, or/and TNFα, or/and BAY 
11–7082. Immunodetection of p65, p53 and the GAPDH loading control, from total MCF7 protein extracts prepared from cell treated with 
the indicated molecules. See Methods for details on the antibodies used.
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Supplementary Figure S3: Gene reporter assay in A549 and H1299 cells. The experiment was performed as described for 
Figure S1. The different concentrations of TNFα and BAY are indicated.
www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2014
	
  	  






	








 









  	  







	
 








Supplementary Figure S4: PLK3, NTN1, ETV7, UNC5B and LAMP3 responsiveness varied among biological repeats 
in HUVEC cells. (A, B) Relative fold change expression of the indicated genes measured by qPCR. The two panels are representative 
of two different results each obtained in two biological replicates. (C) Western blot and immune-detection of p53, p65 and the GAPDH 
loading control.
www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2014
Supplementary Figure S5: Hierarchical cluster analysis. Hierarchical cluster analysis of all the treatments performed in MCF7 
cells and profiled with microarrays, based on the fold changes of 1099 genes whose expression resulted to be significantly changed in at 
least one of the treatments (Euclidean distances and Ward clustering method). D-M (doxo vs mock); T-M (TNFα vs mock); E-M (E2 vs 
mock); DT-M (Doxo + TNFα vs mock); DE-M (Doxo + E2 vs mock); DTE-M (Doxo + TNFα + E2 vs mock).
